Hearing function in adults with Multiple Drug Resistant-TB : a retrospective review. by Kavallieratos, Angela
Hearing Function in Adults with Multiple Drug Resistant-TB: A 
Retrospective Review 
 
A RESEARCH DISSERTATION ON A STUDY PROJECT PRESENTED TO 
 
The Discipline of Speech Pathology and Audiology 
School of Human and Community Development 
Faculty of Humanities 
University of Witwatersrand 
Johannesburg  
 
 
In partial fulfilment of the requirements for the degree M.A. Audiology by Dissertation 
By  
Angela Kavallieratos 
0500021J 
Supervisors: Mr. V de Andrade 
Prof. K. Khoza-Shangase 
 
 
 
 
 
 
 
 
 
 
 
 
July 2012
 ii 
DECLARATION 
 
 
I, Angela Kavallieratos, hereby declare that this submission is my own original work and 
that the assistance I have is detailed in the Acknowledgments of this report. To the best of 
my knowledge and belief, it contains no material which has been accepted for the award 
of any other degree or diploma at any other university or other institute of higher 
learning. I am responsible for the study and conclusions reached.  
 
 
 
 
 
 
 
_________________       __________________ 
 
ANGELA KAVALLIERATOS     DATE 
 
 iii 
 
ACKNOWLEDGEMENTS 
 
The writing of this dissertation has been a significant academic challenge and the 
completion of this study would not have been possible without the contribution and 
support of the following people. To them I extend my sincerest gratitude: 
 
First and foremost, to Victor de Andrade, research supervisor and lecturer at the 
Audiology Department of the University of Witwatersrand, who provided 
unquestionable support and guidance throughout my research process with his 
patience whilst allowing me the room to work in my own way. His unfailing 
belief in me has carried me through this research process.  
 
Prof. Katijah Khoza-Shangase, co-supervisor and HOD of the Speech Therapy 
and Audiology Department at the University of Witwatersrand, who has provided 
experienced and well-structured support during my study. Her wisdom, 
knowledge and commitment to the highest academic standards motivated me.  
 
Kajal Maharaj for her kind words of support, help and friendship during my 
research. Her passion for audiology inspired me to pursue a Masters topic in the 
field of audiology.  
 
The Medical Manager, Rehabilitation staff and nursing staff at Murchison 
Hospital for their permission to use their records, and for their support and 
accommodation of me during the data collection process.  
 
To the statisticians, editors and audiologists that I collaborated with during my 
research, thank you for your professionalism and expertise offered to me during 
my completion of my research.  
 
My family and friends for all their support, encouragement and patience 
throughout my studies. 
 iv 
 
 
My mother, the strongest person I know, for her words of encouragement, 
unfaltering support and love that she offered to me through all my studies.  
 
To the patients I have treated professionally, who reminded me why I chose this 
line of work, whose resilience is incomprehensible, may your quality of live be 
uplifted by the findings of this study.  
 
 
  
 v 
 
ABSTRACT 
 
KwaZulu-Natal has been ranked as having the fourth highest incidence of transmitted 
Multiple Drug Resistant-Tuberculosis (MDR-TB) in sub-Saharan Africa. Substantial 
literature exists indicating the permanent damage that MDR-TB medication has on 
hearing abilities. The purpose of this study was to describe the hearing function of adults 
on long term MDR-TB treatment from Murchison Hospital MDR-TB unit in the Ugu 
District in rural KwaZulu-Natal. The primary aim of the study was to review the possible 
changes in hearing function in a group of adults on long-term treatment for MDR-TB. 
Secondly, the study aimed to estimate the number of adults who may present with 
changes following MDR-TB treatment and establish if relationships exist between the 
audiological findings and factors such as age and gender. The design of the study was a 
retrospective comparative data review of 68 patient records, all of which underwent 
audiological investigations from the start of MDR-TB treatment over a five-month 
period. The study made use of descriptive and inferential statistics to analyse the data. 
Specific inferential statistical analysis included analysis of covariance as well as 
regression analysis. Results from the study showed changes in hearing function in 
Distortion Product Otoacoustic Emissions (DPOAEs) and Pure Tone Audiometry (PTA) 
results at all five audiological sessions and across a range of frequencies. 84% of the total 
sample presented with overall refer readings for DPOAEs and 98.53% of the group of 
adults presented with criteria indicative of ototoxic hearing loss, specifically a bilateral 
mild-profound sloping SNHL on clinical PTA results. In the total sample of patient 
records reviewed in this study, all 68 records showed a change in hearing function, be 
that changes in DPOAE function and/or changes in PTA thresholds, following long-term 
treatment for MDR-TB. Variations in the effects of gender and ear difference were 
minimal and non-significant in all results. Similar presentation, to ototoxic hearing loss, 
of other degenerative conditions exists; however these conditions were accounted for as 
exclusion criteria in this study. Therefore the only remaining cause of possible hearing 
deficit was that of ototoxicity. The study provided valuable data regarding hearing 
function in a population of adults on long-term MDR-TB treatment in South Africa. 
Furthermore, the study has highlighted the need for the establishment of standardised 
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audiological monitoring programmes sensitive to ototoxic hearing loss, within the South 
African context where the incidence of Tuberculosis (TB) and MDR-TB is reportedly 
high.  
 
Key Words: Multiple Drug Resistant – Tuberculosis (MDR-TB), ototoxicity, 
aminoglycosides, Distortion Product Otoacoustic Emissions (DPOAEs), pure tone 
audiometry (PTA).  
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CHAPTER ONE 
INTRODUCTION 
 
1.1 Tuberculosis 
Literature has demonstrated a relationship between anti-tuberculosis medications 
and hearing loss (Duggal & Sarkar, 2007; Human, Hagen, de Jong, Harris, Lombard, 
Christiansen, & Bardien, 2010).  It has been documented that patients on anti-
tuberculosis drugs present with permanent damage to the cochlea (Khoza-Shangase, 
Mupawose, & Mlangeni, 2009), causing a bilateral sensorineural hearing loss (Castillo & 
Roland, 2007).  Internationally, these studies have mainly focused on patients receiving 
first-line drugs administration for tuberculosis (TB); however, South African studies on 
patients with multiple-drug-resistant tuberculosis (MDR-TB) are sparse, hence the 
current study.  
Tuberculosis is a worldwide pandemic (World Health Organization [WHO], 
2009a).  The mycobacterium that causes the highly infectious disease known as TB is 
Mycobacterium tuberculosis (M. tuberculosis).  This bacterium typically attacks the 
lungs, leading to what is known as pulmonary tuberculosis.  This bacterium may however 
also attack any other part of the body, e.g. the kidneys, spine and brain (Dye, 2009), 
causing extra-pulmonary tuberculosis.  TB is a rapidly contagious disease that is spread 
through the air when an individual with active TB expels these bacteria into the air 
through coughing, sneezing, speaking or singing.  People in close proximity need only to 
breathe in the bacteria to possibly become infected (Centers for Disease Control and 
Prevention, 2010).  However, not everyone infected with TB bacteria will become 
actively sick with the disease, as two TB-related conditions exist: latent TB and TB (Dye, 
2009).  In latent TB the bacteria remain dormant in the body for as long as the body is 
able to combat the spread of the disease and shows no signs or symptoms of the disease.  
Latent TB is not contagious.   
However, if the bacteria become active and begin to multiply, the individual runs 
the risk of developing active TB.  Active TB is contagious and people with this condition 
show signs and symptoms of TB, such as chest pain, night sweats, fever, a bad cough that 
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lasts three weeks or longer, chills, coughing up of blood and sputum, weight loss, fatigue 
and loss of appetite (Mayo Foundation for Medical Education and Research, 2011).  In 
individuals with weak and compromised immune systems, such as patients with Human 
Immunodeficiency Virus (HIV), Acquired Immunodeficiency Syndrome (AIDS), the risk 
of developing active TB is much higher than in individuals with uncompromised immune 
systems (Idemyor, 2007).  Both types of TB need treatment to prevent further spread of 
the disease (Dye, 2009).  If not treated, each person with active TB can infect on average 
10 to 15 people a year (WHO, 2009a) and one in every ten of those will become sick with 
active TB in his or her lifetime (WHO, 2009a). 
Global statistics show that more than two billion people, or one third of the 
world’s total population, are infected with the TB bacterium (WHO, 2009a; Centers for 
Disease Control and Prevention, 2011a).  National statistics from Statistics South Africa 
(2009) stated that South Africa had a total population of 49 320 000.  According to the 
most recent South Africa Profile WHO Report (2009c) on Global Tuberculosis Control, 
the incidence of TB is 461 000 new cases per year and 948 per 100 000.  The prevalence 
of TB in South Africa is 336 000 cases and 692 per 100 000, whilst the global average is 
only 206 per 100 000.  In 2008 alone there were 138 803 reported cases of TB in South 
Africa (WHO 2010a).  
Along with incidence and prevalence, mortality rates regarding the TB pandemic 
are also high.  The most recent statistics from WHO reported that a total of 1.77 million 
people died from TB in 2007 (including 456 000 people with HIV), equal to 
approximately 4800 deaths per day (WHO, 2009a).  The vast majority of TB deaths occur 
in developing countries.  It is a disease associated with poverty, with Africa having the 
highest estimated incidence rates (WHO, 2009c).  WHO (2004) asserts that Africans are 
most likely to die from infectious diseases such as TB or pneumonia, with pneumonia 
accounting for 23% of deaths in the African population. 
The natural progression of the disease process has a myriad of symptoms, 
complications, secondary conditions or other disorders; there exists a long list of 
complications which vary according to the site of the TB bacteria.  The most common 
complication in pulmonary tuberculosis is that of respiratory infections and lung tissue 
damage (Mayo Foundation for Medical Education and Research, 2011). Untreated TB is 
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characterized by pulmonary infiltrates, formation of granulomas with caseation (the 
conversion of necrotic tissue to a cheese-like material), fibrosis and cavitation (Dye, 
2009).  Typically, the disease process is that the TB bacillus settles in the alveolar lung 
tissue where infection occurs, causing alveolar-capillary dilation and endothelial cell 
swelling.  Alveolitis results and the infection replicate and spread with an influx of 
polymorphonuclear leukocytes.  These organisms then spread through the body’s 
lymphatic system, the circulatory system and then through the entire body (Springhouse, 
2005).  In the presence of a healthy, uncompromised immune system, the disease will 
arrest (Idemyor, 2007).  However, if the infection reactivates the body’s response, it may 
lead to caseous necrosis.  The caseum may localize, undergo fibrosis, or become exposed 
and form cavities.  These cavities consist of walls studded with TB bacilli that constantly 
multiply and the infected caseous debris may spread through the entire tracheobronchial 
tree of the lung system (Springhouse, 2005; Knechel, 2009).  
1.2 Multiple-Drug-Resistant Tuberculosis 
Poor TB management leads to the development of drug-resistant strains of TB 
(Mayo Foundation for Medical Education and Research, 2011), such as multiple-drug-
resistant tuberculosis and Extensively/Extremely Drug Resistant tuberculosis.  MDR-TB 
is resistant to anti-tuberculosis drugs (Zager & McNerney, 2008), a resistance which 
occurs in M. tuberculosis by random, spontaneous mutations of the bacterial chromosome 
(Knechel, 2009; Villarino, Geiter, & Simone, 1992).  It occurs when there is a substantial 
increase in the proportion of organisms resistant to one or more anti-tuberculosis drugs.  
In particular, MDR-TB is resistant to at least isoniazid and rifampicin (Aziz et al., 2006; 
Human et al., 2010).  The emergence of drug-resistant TB has been seen as a result of 
poor TB control, failure and/or delay in identification, poor isolation measures, delayed 
start of treatment, inadequate and incomplete adherence to treatment, incorrect drug 
dosages, unavailability of drugs and drugs of poor quality (Aziz et al., 2006; Centers for 
Disease Control and Prevention, 2010; Duggal & Sarkar, 2007; Easterbrook, 1996).  
MDR-TB is spread in the same manner as TB; however, risk factors exist for developing 
this disease (Centers for Disease Control and Prevention, 2010).  Drug-resistant forms of 
the disease exacerbate the TB burden.  MDR-TB represents a considerable challenge to 
TB control programmes, because treatment is more complex, more costly, requires more 
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time and is usually less successful (Aziz et al., 2006) as seen in the discussion below.  As 
with TB, death by MDR-TB is usually due to secondary complications (Mayo 
Foundation for Medical Education and Research, 2011).  According to the WHO (2010a), 
the estimated number of MDR-TB deaths globally, excluding those with HIV infection, 
was 97 000 in 2008.  There exist little data providing direct measurement of MDR-TB 
case fatality, creating uncertainty about mortality estimates.  Compounding this issue are 
the incomplete global data on drug-resistant TB.  Even in ideal treatment settings, MDR-
TB cure rates are generally below 50%.  On average, 30% of cases are fatal within two 
years, while the remaining patients continue to be infectious and chronically ill, posing a 
continual threat to communities (Njaramba, 2005). 
According to the WHO (2010b), in 2008 an estimated 390 000 to 510 000 cases 
of MDR-TB occurred worldwide (best estimate is 440 000 cases).  The global incidence 
of this disease is rising (WHO, 2010a; Zignol et al., 2006), as seen in an investigation 
done in 2000 when estimates were only about 273, 000 of new cases worldwide (Dye, 
Espinal, Watt, Mbiaga & William, 2002).  The estimated global incidence of MDR-TB 
episodes among new and relapsed TB cases in 2008 is between 310 000 and 430 000 
episodes, whereas the estimated global incidence for acquired MDR-TB episodes was 
between 83 000 and 110 000, with the best estimate at 94 000 episodes (WHO, 2010a).  
This global increase is caused by the low cure rates due to inappropriate and inefficient 
treatment (Suchindran, Brouwer, & Van Rie, 2009).  A contributing factor to low cure 
rates is the increased cost of treating the disease, which is up to 100 times higher than the 
cost of other drug susceptible diseases (WHO, 2010c).  Despite the efficient Direct 
Observation Treatment (DOT), as recommended by the WHO (2010d), the continued 
spread of MDR-TB lies in poor patient compliance and is therefore a man-made problem 
(Duggal & Sarkar, 2007; Karim, 2008).  These low compliance rates to the treatment 
regimen can be attributed to the lengthy regimens, development of tolerance, drug 
adherence and ototoxic outcomes (Duggal & Sarkar, 2007).    
African countries have the highest incidence rate of TB in the world, while the 
latest estimates of the number of MDR-TB cases in Africa is only 69 000 (Amor, 
Nemser, Singh, Sankin, & Schluger, 2008; WHO, 2010a).  The low proportions of cases 
of MDR-TB are said to be due to the limited data available from most African countries 
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(WHO, 2010a).  Of the 46 countries in Africa, 22 (48%) have provided representative 
data on drug-resistant TB.  The burden of TB drug resistance in Africa remains largely 
unmeasured; however, this is not necessarily the case in South Africa, where surveillance 
data on case detection, culture positivity, drug susceptibility testing coverage and 
accuracy is routinely collected (WHO, 2010d).  Therefore, even with the high incidence 
of MDR-TB in South Africa, there are attempts to keep accurate records that could be 
used for clinical applications. 
Sub-Saharan Africa has been reported to have amongst the highest proportion of 
MDR-TB in the world (Amor et al., 2008).  South Africa is said to have a high rate of 
MDR-TB, as described by the summarised WHO (2010b) findings reflected in Table 1.   
Table 1 
Summary of MDR-TB rates in South Africa among various groups  
 
 
In a study by Zager and McNerney (2008) eight of South Africa’s provinces 
were included in data showing the highest proportion of new MDR-TB cases globally.  
Their study reported that KwaZulu-Natal had an estimated population of 9 146 296 and 
was ranked as having the fourth highest incidence of transmitted MDR-TB in Sub-
Saharan Africa with an estimated 1 286 cases, an estimated incidence of 14.06 cases per 
100,000 and a ranking of 25
th
 in the list of high prevalence MDR-TB countries. 
The other form of drug-resistant TB, namely extremely drug-resistant TB, is 
resistant to second line drugs and the disease becomes virtually untreatable (Kliiman & 
Altraja, 2009).  There is an on-going outbreak of extremely drug-resistant TB and related 
Multiple Drug Resistant TB Percentages and Numbers 
Among new TB cases 1.8 (1.5-2.3)% 
Among previously treated TB cases 6.7 (5.5-8.1)% 
Among incident new and relapse TB cases 10 000 (7 500-13 000)  
Incident acquired MDR-TB case 2 800 (1 900-3 900) 
Among incident total TB cases 13 000 (10 000-16 000) 
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high death rates in South Africa (Zager & McNerney, 2008).  Only three countries, 
Rwanda, the United Republic of Tanzania and South Africa have examined the 
proportion of extremely drug-resistant TB cases among cases of MDR-TB.  South Africa 
has a proportion of 10.5 %, while Rwanda and Tanzania have a proportion of 0% of such 
cases (WHO, 2010a).  
1.3 HIV and Tuberculosis 
As previously mentioned, there exists a close link between HIV and TB since the 
emergence of HIV due to the nature of the immunity destroying HI virus and its 
contribution to the increased incidence of TB (Gandhi et al., 2006; Goozé & Daley, 2003; 
Khoza, 2007; Lawn, Bekker, Middelkoop, Myer, & Wood, 2006).  HIV/AIDS continues 
to be a worldwide pandemic (Khoza, 2007; WHO, 2010b).  South Africa continues to be 
home to the world’s largest population of people living with HIV (Joint United Nations 
Programme on HIV/AIDS [UNAIDS], 2009).  It is one of the countries most severely 
affected by the HIV/AIDS epidemic, with the largest number of HIV infections in the 
world.  UNAIDS’s latest report (2009) states that in 2009 the total number of persons 
living with HIV in South Africa was 5.7 million.  There is a high prevalence and HIV 
transmission rate (UNAIDS, 2009).  None of the studies or surveys regarding HIV/AIDS 
can ever provide a precise number of individuals living with, infected with, dying of 
HIV/AIDS, or died of it.  However, the severity of the HIV/AIDS pandemic is certainly 
evident by the alarming statistics (Khoza, 2007).   
Swanepoel (2006) describes the HIV pandemic as having created a unique and 
overwhelming burden on audiological services in South Africa.  Therefore, given the 
context in which this study has been conducted, one cannot ignore the incidence of 
HIV/AIDS in South Africa.  Moreover, the documented high prevalence of HIV/AIDS in 
the TB infected population in South Africa (UNAIDS, 2009) means that one cannot 
ignore the fact that Sub-Saharan Africa remains the most heavily affected area with 
HIV/AIDS and TB co-infection worldwide (WHO, 2010b).  HIV is reported to alter the 
pathological make-up of TB, therefore complicating the TB infection and creating greater 
co-infection risks for HIV patients (Idemyor, 2007), resulting from both newly acquired 
infection and from reactivation of latent infections (Muma, Lyons, Borucki, & Pollard, 
1997).  HIV-related TB is treatable and curable, but coupled with the poor compliance to 
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TB treatment, gives rise to more cases of MDR-TB (Goozé & Daley, 2003; Suchindran et 
al., 2009).   
There appears to be divergent data on a “standard” or typical type of hearing 
dysfunction seen in patients on HIV treatment (Khoza, 2007).  Treatment success rates 
remain low with patients co-infected with HIV and MDR-TB, due to high mortality rates 
within the HIV-infected population (Muma et al., 1997).  Individuals with HIV/AIDS and 
MDR-TB should be treated in the same manner as those patients who are not HIV-
infected, except for slight adjustments to their regimen.  They should not be treated with 
thiacetazone and should be isolated from both TB and MDR-TB infected patients (Gupta, 
Espinal, & Raviglione, 2008). 
1.4 HIV in the Context of this Study 
Given the large co-infection rates between TB and HIV (WHO, 2010b) and the 
large number of the South African population infected with HIV (UNAIDS, 2009), the 
effects of HIV on hearing cannot be ignored in this study.  There appears to be a large 
discrepancy in data regarding the exact effects HIV has on the auditory system, so much 
so that no specific type or degree of hearing loss can be attributed to the manifestation of 
HIV in patients.  Types of hearing loss include conductive, sensorineural or central 
hearing losses and the degree of loss ranges from mild to profound (Khoza, 2007).  
Therefore, the baseline audiograms and case histories that were reviewed in this study 
were crucial in eliminating confounding variables such as existing conductive and central 
hearing losses.   
Currently there are no data on the incidence of hearing loss induced by 
aminoglycoside in South Africa, despite the common and increasing use of such drugs in 
this country; therefore, a study attempting to provide such data and is considered 
necessary, given the unique resource that this country’s population offers (Human et al., 
2010).  Conducting a study on a South African population and reviewing the effects of 
the treatment of MDR-TB on hearing sensitivity will hopefully shed light on the severity 
and prevalence of hearing loss in such a population and prompt the development of an 
ototoxic monitoring programme to meet the standards of audiological service in South 
Africa. 
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1.5. Gender and Tuberculosis 
Male and female TB patients have differing levels of risk for developing and 
contracting drug resistance based on differences in access to health care services and 
exposure to other risk factors (WHO, 2009b).  The incidence of TB, as well as its 
mortality rate, has been reported to be significantly higher in males than in females 
(WHO, 2009b).  It appears that the trend with TB is that more men are diagnosed with 
TB (58%) and pass away from it than women (WHO, 2010e).  This is not to say that TB 
does not affect women; annually, approximately 700 000 women are reported to die from 
TB and over three million contract the disease globally.  Young adults are mostly 
affected by TB, especially women in their economically and reproductively active years, 
impacting heavily on family systems (WHO, 2009b).  Overall, global data collected by 
the WHO (2010b) show no overall association between MDR-TB and gender of the 
patient.  In South Africa, although a higher number of male than female cases were 
reported with the disease (4826 versus 4615 cases, respectively), data from a total of  
81 794 TB patients of known gender (95% of all patients) indicate that female TB 
patients have a 1.2 times higher chance of harbouring MDR-TB strains than male TB 
patients (WHO, 2010c).   
1.6 Diagnosis and Treatment of Tuberculosis and multiple-drug-resistant TB 
Diagnosis of TB includes radiographic tests such as chest X-rays, a tuberculin 
skin test, sputum smears and cultures to identify the M. tuberculosis disease (Centers for 
Disease Control and Prevention, 2011b).  Treatment of TB depends on the type of TB 
with which the patient presents, i.e. pulmonary tuberculosis or extra-pulmonary 
tuberculosis (WHO, 2010d).  First-line anti-TB drugs are administered according to body 
weight and the combinations of these drugs should conform to the WHO Guidelines for 
TB Treatment (2010d) and are based on the WHO Model List of Essential Medicines 
(2010f).  The first-line TB drugs are a class of anti-bacterial substances known as anti-
tubercular drugs and include isoniazid, rifampicin, pyrazinamide, Ethambutol and 
streptomycin.  Isoniazid is a bactericidal drug against M. tuberculosis, but its method and 
pathway of action is unclear.  It more than likely accumulates intra-cellularly because in 
the bacterium it is converted to a membrane permeable acid called isonicotinic.  
Rifampicin is a type of gyrase inhibitor; specifically inhibiting the resealing of opened 
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DNA strands and thereby acts as a bactericide against M. tuberculosis by inhibiting the 
bacterial enzyme that catalyses DNA template-directed RNA transcription.  Ethambutol 
has anti-tubercular action and pyrazinamide exerts a bactericidal action; however, both 
mechanisms of action are unknown (Lüllmann, Mohr, Ziegler, & Bieger, 2000).  
Streptomycin falls under the umbrella term “aminoglycosides".  It was introduced in the 
1940’s as the first successful drug to combat TB (Begg & Barclay, 1995; Konrad-Martin, 
Wilmington, Gordon, Reavis, & Fausti, 2005).  It is administered intravenously and is 
ototoxic but has minor nephrotoxicity in comparison to its ototoxicity (Lüllmann et al., 
2000).  The audiological side effects of streptomycin include hair cell loss in the basal 
region of the cochlea, high-frequency hearing loss, tinnitus and vestibular symptoms 
(Campbell, 2007).  Similar hearing loss was observed in a study conducted by De Lima, 
Lessa, Aguiar-Santos and Medeiros (2006) where 85% of participants on streptomycin 
for a minimum period of 15 days and a maximum period of eight months presented with 
a bilateral sensorineural high frequency hearing loss.  The degree of hearing loss was not 
indicated in this study. 
After the introduction of streptomycin in the 1940s, other semi-synthetic 
aminoglycosides soon followed, among them kanamycin (in 1957), gentamycin, 
neomycin and amikacin (in 1972) (Begg & Barclay, 1995; Konrad-Martin et al., 2005; 
Schacht, 1998).  Well documented adverse effects of anti-TB drugs have been reported 
(Duggal & Sarkar, 2007) and undoubtedly the most significant limitation of the 
therapeutic use of aminoglycosides is their toxic and adverse effects on the auditory and 
nephritic systems (Konrad-Martin et al., 2005; Schacht, 1998).  Nephrotoxicity, the 
destruction of kidney cells by toxic drugs is usually reversible 
(http://www.medicaldictionary.thefreedictionary.com/nephrotoxicity). 
Ototoxicity was first discovered in 1945 when the first clinical trial with 
streptomycin was done (Begg & Barclay, 1995).  Ototoxicity is the damage to the hair 
cells of the inner ear and vestibular end organs due to toxic drugs (Stach, 2003).  The 
ototoxicity is permanent, because damage to the sensory hair cells and stria vascularis in 
the cochlea occurs (Bardien et al., 2009), often leaving the patient with a bilateral 
sensorineural hearing loss (Castillo & Roland, 2007).  Typically, hearing within normal 
limits in adults is between 0 and 25 dBHL and between 0 and 15 dBHL in children 
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(Roeser & Clark, 2007).  People receiving medication with ototoxic side effects may 
present with hearing that falls outside of these normal levels.  The type of medication 
used to combat the MDR-TB is known to be highly ototoxic (Duggal & Sarkar, 2007; 
Easterbrook, 1996; Steyger & Karasawa, 2008), with kanamycin and amikacin reported 
to be exclusively cochleotoxic (De Jager & Van Altena, 2002; Duggal & Sarkar, 2007; 
Mudd, Edmunds, Glatz, Campbell & Rybak, 2010).  
Part of TB management includes the need for proper and effective health care 
systems (WHO, 2009a).  Direct observation treatment of TB involves assigning 
caregivers or health workers to observe the administration of anti-TB drugs. The goal of 
this method of treatment is to monitor the treatment regimen and reduce the development 
of resistant organisms (Centers for Disease Control and Prevention, 2011c). Direct 
observation treatment has a success rate of 74% nationally in South Africa (WHO, 
2009c).  
TB requires combined drug treatment to prevent the emergence of resistant 
mycobacteria (Lüllmann, et al., 2000).  Resistance occurs when the plasmids in the 
cytoplasm produce inactivating enzymes, which provide resistance to aminoglycosides’ 
bonding action; therefore impairing conveyance of the drugs microbes (Begg & Barclay, 
1995).  “Multiple-drug-resistant” implies resistance mostly to isoniazid and rifampicin; 
therefore these drugs are seldom used to treat MDR-TB.  Drug susceptibility tests are 
then done to prove susceptibility on a culture, and then aminoglycosides are used rather 
than regular anti-TB drugs (Human et al., 2010; Lüllmann, et al., 2000).  MDR-TB  
treatment encompasses the aminoglycoside drugs such as amikacin, streptomycin, 
kanamycin and gentamycin (Duggal & Sarkar, 2007) and can include some of the first-
line drugs and drugs of other classes of antibiotics (Bardien et al., 2009; Gibbon, 2005).  
Literature strongly suggests that the initial treatment regimen should consist of at least six 
drugs: an aminoglycoside, a fluoroquinolone, a thioamide, pyrazinamide and as many 
residual first-line oral drugs as possible (Duggal & Sarkar, 2007; Gupta et al., 2008).  
This regimen can be chosen on the basis of a patient’s history and previous susceptibility 
tests results or on the basis of the local community’s resistance pattern.  Drug 
administration can begin even while further susceptibility testing is being done.  Once 
susceptibility data is available, the patient should be administered at least four drugs, of 
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which at least two should be bactericidal and should include an intravenously 
administered drug (i.e. an aminoglycoside) and a fluoroquinolone.  The injectable drug 
should be administered for as long as possible and for a minimum of six months.  Total 
chemotherapy should last 24 months.  Monthly status monitoring should be done using 
sputum smear and culture testing.  Ideally, drug regimen modification should be 
implemented when a patient does not respond to treatment based on drug-resistant pattern 
detected by continued susceptibility testing.  Once patients complete treatment, they 
should be monitored for at least one year for early detection of relapses.  This process of 
combining first-line and second-line drugs is said to produce a higher treatment success 
rate (Gupta et al., 2008).  Literature states that patients on a four-drug regimen may show 
a faster negative result sputum culture and have a better chance of cure with no relapse, 
even if the full course is not completed, than a patient treated for the same length of time 
on a three-drug regimen.  Villarino et al. (1992) suggest at least 18 months of drug 
therapy when a patient is diagnosed with MDR-TB and preferably continue for 24 
months after conversion to negative in a patient’s sputum culture.  As with typical 
emergence of MDR-TB, many patients discontinue their treatment and consequently do 
not recover.  They are then forced to resume a prolonged, more toxic drug regimen which 
may increase their chances of ototoxicity (De Lima et al., 2006).  Some drug regimens 
range from 14 days (De Jager & Van Altena, 2002) up to several years (Duggal & Sarkar, 
2007).  
There exits great variability in the dosage strategies of aminoglycosides, which 
lead to individualized dosage strategies being implemented dependent on the clinical 
situation.  Aminoglycosides are concentration-dependent in order for them to work 
effectively against bacteria; Begg and Barclay (1995) suggested that they are better given 
less frequently in larger doses.  In contrast to the above dosage strategy, Lüllmann et al. 
(2000) suggested that smaller doses are sufficient because the antibacterial effect of the 
individual drug substance are additive, thereby lowering the risk of individual adverse 
effects.  Traditionally, dosing has been on a daily or 3 times per week basis due to the 
slow rate at which mycobacteria replicate; however, it has been unclear which 
pharmacological parameter is responsible for the development of toxicity (Peloquin et al., 
2004).  Studies were conducted where toxicity of the cochlear, vestibular and renal 
 12 
 
systems were compared using the 2 dosing routines mentioned above.  No significant 
difference was found between the two routines (Begg & Barclay, 1995; Peloquin et al., 
2004).  As with first-line drugs, dosages of second-line drugs are also dependent on the 
patient’s body weight (Li & Steyger, 2009).   
A study conducted by Peloquin et al. (2004) compared the incidences of toxicity 
associated with the two most common dosing regimens: daily versus three weekly 
dosages including aminoglycosides, streptomycin, kanamycin and amikacin.  Therapy 
duration ranged from one to 137 weeks.  Conventional audiograms were used in order to 
ascertain the incidence of ototoxicity every two weeks in a sample size of 87 patients 
diagnosed with M. tuberculosis.  They defined ototoxicity as a ≥ 20 decibels (dB) 
sensorineural hearing loss from baselines in either ear at any frequency.  According to 
their findings ototoxicity was not associated with the size or frequency of the 
aminoglycoside dosage; rather, it was associated with old age, longer treatment duration 
and total dosage received.  Of the sample, 32 out of the 87 patients had ototoxic hearing 
loss with onset mostly occurring after nine weeks of receiving treatment, but some 
participants showed audiological changes as earlier as five weeks after starting treatment.  
Most participants showed evidence of hearing loss in frequencies ≥ 2 000 Hertz (Hz), 
with five out of 36 participants showing loss in both the low and high frequencies.  
Streptomycin was found to be the least ototoxic substance.  Patients reported on 
subjective hearing loss and associated symptoms, such as tinnitus, before conventional 
audiometry detected hearing changes.  The study did not include other audiological 
evaluations that are more specific to ototoxic hearing changes, such as high frequency 
audiometry (HFA) and otoacoustic emissions (OAEs).  Furthermore, they did not exclude 
participants with a history of hearing loss and didn’t exclude participants with age related 
hearing losses (Peloquin et al., 2004).  Therefore, it appears necessary to investigate 
hearing loss exclusively related to ototoxicity and to control for variables such as age and 
previous hearing loss which may influence the findings of such an investigation.  
Peloquin et al. (2004) suggested full dosages for the shortest possible period of time for 
the treatment of MDR-TB as opposed to lower, more prolonged dosages or maximum-
capped doses.  Streptomycin was found to be less ototoxic than kanamycin and amikacin.  
The researchers emphasised the need for clinicians to be vigilant in monitoring, even in 
 13 
 
short dosage regimens (Peloquin et al., 2004).  The study was not an audiological study, 
but focused on dosage regimens; however, it did highlight the need for ototoxic-specific 
monitoring programmes.    
1.7 Pharmacology and Pharmacotoxicology  
A large body of literature exists on the mechanisms, pathophysiology and 
pharmacology of aminoglycosides; however, the specific intra-cochlear trafficking of 
aminoglycosides in ototoxicity is still unknown (Begg & Barclay, 1995; Li & Steyger, 
2009; Steyger & Karasawa, 2008; Mudd et al., 2010).  
Aminoglycoside antibiotics consist of glycoside-linked amino sugars, i.e. two or 
more amino sugars connected to an aminocyclitol nucleus.  The different 
aminoglycosides are distinguishable by their different amino sugars (Begg & Barclay, 
1995; Lüllmann et al., 2000).  They inhibit protein synthesis and alter the membranes of 
cells.  They contain numerous hydroxyl groups and amino groups that can bind protons, 
making these compounds highly polar, poorly lipid membrane permeable; they show no  
enteric absorption.  Therefore, for the treatment of serious infections, aminoglycosides 
must be administered intravenously (e.g. streptomycin, amikacin, and kanamycin) (Li & 
Steyger, 2009; Lüllmann et al., 2000).  Aminoglycosides’ mechanism of access to the 
bacterial interior is by the use of two bacterial carrier systems.  The first transport system 
allows uptake across the lipid’s inner membrane. The rate of crossing is limited and can 
be blocked by calcium and magnesium ions, low pH and anaerobic conditions.  The 
second transport phase is energy dependent and the drug accumulation is much faster 
than in phase one (Lüllmann et al., 2000). Aminoglycosides are dependent on bactericidal 
concentration activity and intermittent doses are required to combat bacterial resistance 
(Peloquin et al., 2004) and aminoglycoside ototoxicity is most likely related to multiple 
factors (Mudd et al., 2010).  
The second phase transport system results in protein synthesis inhibition and 
alteration of the cell membranes (Lüllmann et al., 2000).  More specifically, 
aminoglycosides bind to the 30S ribosome and inhibit bacterial protein synthesis.  They 
act on gram-negative bacilli.  They disrupt mitochondrial protein synthesis, interact with 
transitional metals such as iron and copper and aid in the formation of oxidation 
compounds that can contribute to the formation of undesirable oxygen and nitrogen free 
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radicals.  These free radicals interact with protein and DNA in the nucleus and 
consequently cells self-destruct due to the oxidative stress.  Hair cell destruction follows 
as the body’s antioxidant defence system fails to neutralize these free radicals (Konrad-
Martin et al., 2005).  With the formation of nitric oxide the concentration of this oxide 
will increase and form peroxynitrite radicals that also induce cell damage and death.  A 
cascade effect follows with cell contents leaking out (apoptosis), which is the primary 
mechanism of cell death (Begg & Barclay, 1995; Mudd et al., 2010).  
The particular mechanisms by which aminoglycosides cause ototoxic damage are 
still largely unknown; however, what is known is that ototoxicity is said to possibly be 
the result of aminoglycoside and phosphoinositol binding, which leads directly to cell 
membrane alteration (Begg & Barclay, 1995).  This process of cochlear hair cell damage 
occurs when the aminoglycosides cross the blood-labyrinth barrier and enter the fluids 
contained in the cochlear organs.  The aminoglycosides enter the cochlear hair cells via 
their apical membranes that are immersed in endolymph fluid in the scala media of the 
cochlea, implying filtration from the endolymphatic scale media.  Once they penetrate 
this fluid, they permeate non-selective cation channels of the hair cells and generate toxic 
reactive oxygen agents and interfere with other cellular pathways. Once the 
aminoglycoside drug has been taken up in the cell, it can induce increased calcium levels 
and alter intracellular conditions (Li & Steyger, 2009) which lead to hair cell death and 
permanent hearing loss (Li & Steyger, 2009; Steyger & Karasawa, 2008). 
Aminoglycosides have also been found present in the perilymphatic fluid (Li & Steyger, 
2009).  Tubercular cells, such as those found in the kidney and sensory cells of the 
vestibular system are susceptible to permanent damage (Lüllmann et al., 2000).  
Vestibular damage is also evident and occurs in the crista ampullaris, resulting in ataxia 
and nystagmus.  These ampulla cells, along with cochlear cells cannot regenerate after 
being damaged (De Jager & Van Altena, 2002).  Therefore, studies investigating the 
effects of ototoxic hearing loss are needed in order to advocate for ototoxic monitoring 
whereby permanent cell damage related to ototoxic hearing loss may be supervised and 
appropriate measures may be taken (Duggal & Sarkar, 2007; Campbell, 2007; Rappaport 
& Provencal, 2002; Vasquez & Mattucci, 2003).  It appears necessary to study the 
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audiological consequences of ototoxicity in MDR-TB so that ototoxic-specific 
monitoring programmes can be implemented.  
The above ototoxic process results in typically progressive, bilateral, symmetric 
and sensorineural hearing loss and may include symptoms such as tinnitus and difficulty 
with hearing in noise (Konrad-Martin et al., 2005; Steyger & Karasawa, 2008).  Hearing 
loss is typically in the high frequencies (Duggal & Sarkar, 2007), although it may not 
always remain so.  Hair cell damage is systematic and in the early stages the damage 
starts within the lower turns in the cochlea which are responsible for the higher 
frequencies; it then gradually moves up towards the apex of the cochlea that is 
responsible for the lower frequencies (De Jager & Van Altena, 2002; Schacht, 1998).  
The damage tends to progress from outer hair cells to inner hair cells, to supporting cells 
to central neural structures; this pattern of progression explains the high frequency 
hearing loss first seen with ototoxic treatments (Duggal & Sarkar, 2007).  In addition to 
the above, research supports the notion that sufficiently high doses of and continued 
exposure to such ototoxic drugs lead to damage of progressively lower frequencies 
(Duggal & Sarkar, 2007; Li & Steyger, 2009).  Furthermore, because cochlear sensory 
hair cells take a long time to clear aminoglycosides (as opposed to other organ cells that 
clear aminoglycosides at a normal rate), they retain the drugs, which results in the 
progressive hearing loss associated with ototoxic damage (Li & Steyger, 2009; Mudd et 
al., 2010).  
Despite the typical type of hearing loss associated with ototoxic drug regimens, 
inter-patient variations do exist and ototoxicity can be unpredictable (Begg & Barclay, 
1995; Mudd et al., 2010).  Variations in degree and range of hearing loss, susceptibility to 
ototoxic hearing loss and onset of hearing loss are individualistic, but contributory factors 
include dosage, genes, physiology and biochemistry.  Some studies have also suggested 
that the severity of the hearing loss is related to age and/or the degree of previous hearing 
loss (Konrad-Martin et al., 2005).  Other studies evidenced that ototoxicity is more 
common in adults than in neonates and children (Mudd et al., 2010).  Risk factors for 
ototoxicity include larger doses, higher blood levels, longer duration of treatment, 
advanced age, genetic factors, compromised renal systems, pre-existing hearing 
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difficulties, history of ototoxic related hearing loss and toxic medications (Konrad-Martin 
et al., 2005). 
1.8 Side Effects of Hearing Loss 
In light of the negative side effects on the auditory system highlighted earlier, 
there are also the side effects of post-lingual hearing loss. The side effects of post-lingual 
hearing loss have been reported to include psychosocial effects such as depression, 
irritability, fatigue, paranoia, withdrawal and isolation.  In addition to these effects, if the 
hearing loss occurs in adulthood, these adults need to cope with social changes in their 
work, social and family lives (Ross & Deverell, 2004).  Hearing impairment is not 
generally considered to be a life-threatening condition but it does impact severely on 
quality of life (Khoza-Shangase et al., 2009).  Psychosocial, cognitive-linguistic, 
vocational and interpersonal aspects of a patient’s life are detrimentally affected 
(Swanepoel, 2006).  High death rates associated with MDR-TB (Amor et al., 2008; 
WHO, 2010b) labelled MDR-TB as life threatening and therefore treatment warrants the 
use of ototoxic medication.  Medical professionals have to make the judgment call that 
the risk of toxicity from the MDR-TB regimen is outweighed by the possible life-saving 
benefit of the regimen (WHO, 2010a).  Although preserving life is paramount, preserving 
the quality of life for the patient should also be a treatment goal (Fausti, Wilmington, 
Helt, P.V., Helt, W.J & Konrad-Martin, 2005).  According to the WHO Guidelines for the 
Treatment of TB (2010d), patients should be monitored for the known adverse side effects 
of drug-regimens and major adverse reactions in patients with MDR-TB, such as hearing 
loss, which should be promptly managed in hospital. 
Hearing loss can develop soon after commencement of drug therapy and will 
continue in a progressive manner after the ototoxic treatment has been discontinued.  
Continued audiological management is therefore necessary to confirm stable hearing 
thresholds and to evaluate rehabilitation measures.  Literature affirms that these changes 
and effects of the aminoglycoside drugs can be seen after five days following the 
commencement of aminoglycoside therapy (De Jager & Van Altena, 2002) and that it 
may continue for up to four weeks after drug administration has been terminated (Li & 
Steyger, 2009).  The time of onset of hearing loss is unpredictable.  It may be evident 
after a single dose of treatment, or several weeks after treatment has ended.  Regardless 
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of onset, the hearing loss is permanent and has severe communication and social 
consequences.  Monitoring and management programmes therefore need to be 
established in order to minimize the adverse effects of these life-saving treatments.  Due 
to the latency effect that aminoglycosides have on hearing function, monitoring should 
ideally continue for at least six months after the cessation of treatment (Mudd et al., 
2010).  A study on the treatment of MDR-TB by Gupta et al. (2008) suggested that 
specific management strategies should be implemented as soon as adverse reactions to 
drug administration such as ototoxicity, nephrotoxicity and other medical conditions 
occur.  Gupta et al. (2008) went on to say that adverse reaction management should 
include the following steps in the order provided: divide dose, use ancillary drugs, reduce 
the dosage or replace/exclude drug.  Better patient management for individuals with 
MDR-TB is therefore necessary (Villarino et al., 1992).  
Numerous literature sources highlighted the need for any patient who is in poor 
medical health and is receiving large or prolonged doses of ototoxic medications to be 
incorporated into an audiological monitoring programme (Konrad-Martin et al., 2005). 
Furthermore, the use of aminoglycosides is unavoidable, but largely unregulated in 
developing countries such as those in Africa.  The emergence of drug resistant TB has 
caused an increase in the use of aminoglycosides (Konrad-Martin et al., 2005; Schacht, 
1998).  Due to this increase an attempt needs to be made to slow down and monitor 
ototoxic hearing loss (Campbell, 2007).  Studies have been conducted on the 
development of a protective therapeutic mechanism in the form of antioxidants (Schacht, 
1998; Steyger & Karasawa, 2008), but this does not always appear feasible or available 
due to its complex and expensive nature, especially in developing countries (Schacht, 
1998).  A combination of anti-oxidant agents, iron chelators and aminoglycoside 
absorption inhibitors are required to prevent ototoxic damage (Li & Steyger, 2009; Mudd 
et al., 2010).  
1.9 Research Rationale 
Previous studies that investigated hearing function in TB revealed ototoxic 
irreversible hearing loss, with permanent damage to auditory and vestibular systems 
(Khoza-Shangase et al., 2009; Konrad-Martin et al., 2005; Li & Steyger, 2009; Peloquin 
et al., 2004; Schact, 1998).  These studies only investigated the effects of first-line anti-
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TB drugs, but not the effects of second-line anti-TB drugs (i.e., anti-multiple-drug-
resistant TB drugs).  A study by Duggal and Sarkar (2007) investigated the prolonged re-
administration of ototoxic drugs on hearing.  These authors study stated, “Initial ototoxic 
drug exposure typically affects cochlear regions coding the high frequencies.  Continued 
exposure (to ototoxic drugs) results in spread of damage to progressively lower 
frequencies” (Duggal & Sarkar, 2007, p. 1473).  This finding has implications for the 
stage at which a patient may actually report ototoxic symptoms to health care providers, 
because the symptoms may not affect their speech frequencies for some time (Khoza-
Shangase et al., 2009) and therefore they may only realize much later that there has been 
a change in their hearing abilities.  Inclusion of audiological monitoring programmes 
would be crucial in detecting early changes in auditory functioning (Duggal & Sarkar, 
2007; Khoza-Shangase et al., 2009; Konrad-Martin et al., 2005). It is therefore critical 
that the audiological effects of second-line drugs, such as those used in MDR-TB, be 
investigated (Khoza-Shangase et al., 2009).  This study focuses on hearing function in 
adults on long-term treatment for MDR-TB. 
MDR-TB and TB have been – and continue to be – world wide epidemics (Amor 
et al., 2008; WHO, 2010b; Zignol et al., 2006) and the effects of TB treatment are known 
to cause irreversible hearing loss (Bardien et al., 2009; Duggal & Sarkar, 2007; 
Easterbrook, 1996; Schacht, 1998; Steyger & Karasawa, 2008).  However, there appears 
to be no standardised guideline for monitoring ototoxicity in patients on ototoxic drugs 
yet (Duggal & Sarkar, 2007; Vasquez & Mattucci, 2003; WHO, 2010d). 
The WHO’s most recent Guidelines on the Treatment of TB (2010d) endorsed a 
symptom-based approach to the side effects of anti-TB drugs and stated that treatment 
and management of TB included addressing all the patient’s needs.  These guidelines 
acknowledged that a most effective regime for isoniazid resistant TB is unknown and that 
no evidence based research has been conducted with ethambutol (an anti-TB drug) and 
ototoxicity.  Often the use of ototoxic treatment is unavoidable for preserving human life; 
however, investigating the long-term effects of such medication and instituting a 
monitoring programme will provide better care for an improved quality of life for such 
patients (De Lima et al., 2006).  In a study by Bardien et al. (2009) no data were found on 
the incidence of hearing loss induced by aminoglycoside in South Africa.  The study 
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went on to highlight the need for regular audiological monitoring throughout the 
treatment of MDR-TB (Bardien et al., 2009). 
American Speech-Language-Hearing Association (ASHA) Guidelines on 
ototoxicity (1994) stated that the responsibility of designing and implementing an 
auditory monitoring programme for ototoxicity rests with the audiologist.  According to 
ASHA (2004), the scope of practice of an audiologist includes the provision of services 
that optimize and enhance the ability of an individual to hear and to communicate in 
his/her everyday environment, while the overall goal of audiological services is to 
improve the quality of life for all of these individuals.  The ototoxic effects of MDR-TB 
medication emphasise the need for early hearing loss identification, for appropriate 
management in the form of rehabilitative audiology, hearing amplification, education and 
counselling (Khoza-Shangase et al., 2009).  In the case of this research, the psychological 
effects are greater, because the patients have a chronic life threatening illness and are 
facing permanent hearing loss.  The need for audiologists to become involved in the 
intervention and management of patients with MDR-TB derives from the 
multidisciplinary approach of comprehensive care for complex conditions.  There is no 
conventional structure for a multidisciplinary team in the monitoring and management of 
MDR-TB and the structure of such a team will be dependent on the specific needs of the 
community to be served.  In South Africa, the audiologist is considered a paramedical 
care provider (Ross & Deverell, 2004) and may not be one of the health care 
professionals with whom patients first come into contact with at their first diagnosis with 
TB.  
According to Duggal and Sarkar (2007) early identification of ototoxicity would 
allow drug regimens to be adjusted in order to curtail and/or prevent permanent hearing 
loss.  Furthermore, appropriate planning for audiological rehabilitation and counselling 
should be implemented.  Despite research attempts to create a milder, less toxic drug 
concentrate, ototoxicity can occur through even a single dose, highlighting the need for 
ototoxic monitoring programmes when such drugs are used (Campbell, 2007; Rappaport 
& Provencal, 2002; Vasquez & Mattucci, 2003).  Currently, there is no programme in 
South Africa to monitor ototoxic effects of HIV and TB medications.  In a study 
conducted by Khoza-Shangase et al. (2009), they highlight the need for the development 
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and implementation of an ototoxic monitoring programme as part of standard TB patient 
care.  Furthermore, the inclusion of audiologists in the team management of TB has also 
been highlighted (ASHA, 2010; Campbell, 2007; Martin & Clark, 2003; Ross & 
Deverell, 2004).  Zignol et al. (2006) called for an expansion in appropriate diagnostic 
and treatment services for patients with MDR-TB in low resource settings such as South 
Africa.  
Some studies investigated the effects of second-line drug treatments and 
ototoxicity on the hearing status of patients on long-term MDR-TB treatment (Duggal & 
Sarkar, 2007; Jager & Van Altena, 2002).  Few studies, if any, have considered gender 
differences, age limits (presbyacusis), or included HFA or OAEs as part of the 
audiological follow-up.  HFA and OAEs have been shown to be very sensitive and 
appropriate in ototoxic monitoring (Khoza, 2007; Khoza-Shangase et al., 2009).  Anti-TB 
drugs are known to be toxic to cochlear hair cells (Bardien et al., 2009; Duggal & Sarkar, 
2007) and OAEs measure hair cell function in the cochlea (Campbell, 2007).  Ototoxic 
drugs typically cause high-frequency hearing loss and HFA has been found to be suitable 
for testing the basal region of the cochlea which is responsible for the high frequencies 
(Beiter & Talley, 1976; Campbell, 2007; Wolfgang, Schönfeld, Mansmann, Fischer, & 
Gross, 1998).  There exists data showing gender differences with regards to TB and 
MDR-TB epidemiology that cannot be overlooked in this study (WHO, 2009b; WHO, 
2010a).  This project will therefore report on gender differences (if any) and on HFA and 
OAEs in the audiological monitoring of ototoxic drug regimens.  
In a retrospective study by De Jager and Van Altena (2002) on the ototoxicity of 
aminoglycosides in patients on long term second-line TB treatment, they found that 
hearing is greatly affected by long-term use of aminoglycosides.  In their study, long term 
treatment was defined as a period of 14 days, although the treatment regimen may carry 
on for longer periods (Bardien et al., 2009). There was no audiological monitoring during 
the treatment in this study, because the audiological information was limited to a baseline 
and/or exit audiogram only.  Some of the cases had no baseline audiogram to compare 
hearing function before and after the commencement of treatment. The study by De Jager 
and Van Altena (2002) did not have a uniform time interval between measures. Similarly, 
no HFA or OAEs were conducted as part of the audiological follow-up, despite their 
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sensitivity to ototoxic monitoring (Khoza, 2007; Khoza-Shangase et al., 2009).  They did 
however take into account factors such as age and gender, but not previous, existing or 
conductive hearing loss.  
In a cohort study by Duggal and Sarkar (2007), audiological assessments began at 
base-line level and follow-up was conducted every two months until completion of drug 
therapy (mean length of therapy was 20.3 months).  All patients with previous or current 
hearing loss of any type as well as those with a history of previous ototoxic drug 
regimens were excluded from the study.  Pure tone audiometry ranged from 125Hz to 
8kHz and included air and bone conduction thresholds.  This study included baseline and 
renal function tests and excluded patients with abnormal renal and/or liver results.  The 
patients’ age ranged from 17 to 65 years and they were on a drug regime that included 
anamycin, kanamycin and capreomycin (similar toxicity to aminoglycosides).  Those on 
two ototoxic drugs were excluded from the study.  The study found that a number of 
patients presented with sensorineural hearing loss on either ototoxic drug.   
The current study investigated the hearing function in adults on long term MDR-
TB treatment and includes HFA and OAEs, explores gender differences and 
presbyacusis, and was conducted in South Africa.  It was felt that such a study would 
contribute to the field of MDR-TB in this context. 
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CHAPTER TWO 
METHODOLOGY 
 
2.1  Main Aim of the Study 
The main aim of the study was to describe the hearing function in adults on long-
term treatment for MDR-TB. 
2.2  Sub Aims of the Study  
The sub aims of the study were: 
1. To review for possible audiological changes in adults receiving MDR-TB 
treatment from the commencement of MDR-TB treatment over a five month 
period  
2. To estimate the number of adults who may present with changes in hearing 
following long-term MDR-TB treatment at a district hospital in KwaZulu-Natal. 
3. To look for possible relationships between the audiological findings and factors 
such as age and gender in a group of adults receiving long-term MDR-TB 
treatment. 
2.3 Hypotheses of the Study 
The null hypothesis for the study was that there are audiological changes in adults 
receiving long-term MDR-TB treatment.  
The alternate hypothesis stated that there are no audiological changes in adults 
receiving long-term MDR-TB treatment. 
2.4  Research Design  
The design of the study was that of a retrospective comparative data review of 
hospital records from an MDR-TB unit. The research project was based on data that 
already existed before the research aim was formulated.  The investigator was, therefore, 
dependent on participant classification and criterion-variable measurements performed at 
a different time to that of the data collection. A disadvantage of utilizing this 
retrospective research design was that a different person conducted the investigations at a 
different time, leaving room for biases and inaccuracies, thus raising questions about 
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reliability and validity of the existing data (McBurney & White, 2007; Schiavetti & Metz, 
2002). However, in order to address these concerns about reliability and validity, the 
researcher made use of the research site’s well-documented patient records, equipment 
calibration records and measurement methods, and the site’s audiology department made 
use of an audiological assessment protocol based on international standards and research 
(ASHA, 1994; 2004; Campbell, 2007; Fausti et al., 1999). Comparative research was 
therefore also employed to allow the investigator to control participation selection during 
the data collection (Schiavetti & Metz, 2002). A record review study was useful in this 
instance, where it was prospectively and logistically unfeasible to conduct an experiment 
relating the variables of interest (McBurney & White, 2007) due to the long-term nature 
of the study and high mortality rates of such patients in interest. A retrospective 
comparative record review was therefore useful (McBurney & White, 2007) and was 
deemed appropriate for this study.  
2.5 Description of the Sample 
The demographic information has been included as part of the sample description 
rather so that the sample composition is established from the outset and will be referred 
to later in the results and discussion. 
Table 2 
The age demographic profile of the sample reviewed in the study (N = 68) 
 
Factor N Range Minimum Maximum Mean Percentage Std. 
Deviation 
Age 68 31 18.00 49.11 33.40 N/A 8.412 
Male 33 31 18.00 49.11 35.64 48.53% N/A 
Female 35 26 18.00 44.11 31.29 51.47% N/A 
 
As seen in Table 2, 68 patient records were reviewed and included in this study; 
patient records included both male and female records. The age ranged from 18.00 years 
to 49.11 years with a mean age of 33.4 years.  
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2.5.1 Sample Selection Criteria - Sample inclusion criteria: 
- All the patient records from the sample had to be adults, between 18.00 years and 
49.11 years of age because the study was focused on adults with MDR-TB and its 
effects. As stated in Section 28 of the Bill of Rights (2009/1996), the legal age of 
the start of adulthood is age 18 and a child is any person who is under the age of 
18 years. Children were excluded from the current study as normative data 
pertaining to children regarding hearing function differs to that of the normative 
data pertaining to adult findings on hearing loss (Roeser & Clark, 2007). Studies 
have highlighted that there is a much higher incidence of middle ear pathologies 
(an exclusion variable in this study) in the paediatric population and furthermore, 
audiological test sensitivity and results differ in paediatric and adult populations 
(Khoza, 2007). 
- Only records including a baseline audiogram (including otoscopic examination, 
screening DPOAEs and HFA) and consistent audiological monitoring over a five-
month period from the start of MDR-TB treatment and including an exit 
audiogram were considered. In general, the adherence to drug treatment for 
MDR-TB is poor in all populations (WHO, 2010a); given this fact many patients 
may abort full-term drug regimens. Therefore five months of consistent 
audiological monitoring was used to gain a large enough sample size.  
2.5.2 Sample Selection Criteria - Sample exclusion criteria: 
- Patient records that indicated older than 50 years during their time at Murchison 
Hospital were excluded from the study as an attempt to rule out the additional risk 
of ototoxicity, which is higher in the elderly (Peloquin et al., 2004) and hearing 
loss as age related phenomenon (presbyacusis). Presbyacusis can be described as 
the sensory, neural, vascular, mechanical and synaptic changes that the auditory 
systems undergo with age. It is hearing loss caused by the physiological process 
of aging. As these components change, hearing acuity decreases over time but 
varies amongst individuals (Jordan & Roland, 2000). Literature suggests that the 
increased risk of ototoxicity is associated with older age (Begg & Barclay, 1995; 
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Mudd et al., 2010; Peloquin et al., 2004). Therefore the records of persons older 
than 50 years were excluded from the data for analysis so as not to introduce the 
confounding variable of presbyacusis.  
- Furthermore, records with any history of any hearing loss prior to starting the 
MDR-TB treatment were excluded from the study by reviewing the case files and 
past case histories, thereby not including their results in the data analysis so as to 
control for pre-existing hearing loss which could confound the research findings.  
Also, records that indicated middle ear pathologies, for example, any other 
tympanogram besides a Type A tympanogram or if there was a complete blockage 
of the ear canal due to cerumen, were excluded from the record review because 
conditions such as middle ear pathologies obstruct the transmission of sound 
through the outer and/or middle ear systems, resulting in a conductive hearing 
loss (Martin & Clark, 2003) and influence OAE findings (Castillo & Roland, 
2007). Many studies investigating hearing sensitivity in patients having MDR-TB 
have not found MDR-TB drug regimens to cause typical conductive hearing loss 
(Duggal & Sarkar, 2007; Peloquin et al., 2004).  
- Records that showed inconsistent monthly monitoring, i.e. patients who had 
regularly missed hearing assessments, were excluded from the sample to ensure 
consistent, long term data. 
2.6 Sampling Procedure 
A non-probability convenience sampling technique was used in this study as this 
technique is useful when descriptive statistical methods are being used (Grove, 2005). 
Patients at the MDR-TB unit at Murchison Hospital were referred to the audiology 
department within a week of admission and start of MDR-TB treatment. The sample was 
limited to the accessibility of patient records which were part of the MDR-TB 
audiological-monitoring programme and adhered to the inclusion criteria set out for this 
study. Many patient records did not include at least five monthly audiological 
assessments because of the poor adherence to MDR-TB treatment (CDC, 2010) and high 
mortality rates common in MDR-TB patients (WHO, 2008). Random sampling may have 
been inappropriate and problematic to achieve (Trochim, 2006) given the specific 
inclusion criteria required for this study. Purposive sampling was used for the sample and 
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research site, as purposive sampling is utilized when the researcher targets a particular 
group with information that is specific to the central themes being researched (Kemper, 
Stringfield & Teddlie, 2003). The research site was purposefully selected, as this site has 
the appropriate patient records with the information required by the researcher and is 
representative of the population of interest in the study.   
2.7  The sample – Sample Size and Distribution 
The sample consisted of 68 past patient files, of both male and female patients 
that met the strict sample inclusion criteria, which were available and these were 
reviewed from Murchison Hospital MDR-TB unit in the Ugu District in rural KwaZulu-
Natal. The Murchison Hospital Audiology Department started the MDR-TB audiological 
monitoring programme in April 2008, and it is still running presently. Since the start of 
the audiological monitoring programme until June 2010, 270 MDR-TB patients had been 
seen; only patients from this time period were considered as patients after June had not 
been seen for at least five consecutive sessions. Ethical clearance was granted in 
September 2010 for the study, so the review date and data collection took place in 
September 2010. The sample size of 68 patient records may appear small in relation to 
the total number of MDR-TB patients seen at Murchison Hospital, but this smaller 
sample size was because of the exclusion of patients who presented with middle ear 
pathologies, did not attend for four consistent follow-up sessions due to acute illness, 
those who defaulted treatment and hospital care, or those who passed away. Murchison 
Hospital provides a district level of care services for a large rural area of KwaZulu-Natal 
with 260 beds, with only a small portion available for the MDR-TB unit. It also has eight 
referring satellite clinics. The hospital serves a population of approximately 200 000 
people. The hospital has a well-established rehabilitation unit with an audiology 
department, which keeps monthly audiological records on the MDR-TB patients. 
KwaZulu-Natal has one of the highest incidences of transmitted MDR-TB in sub-Saharan 
Africa (Zager & McNerney, 2008) and therefore appeared to be well suited to study 
hearing levels in persons with MDR-TB. At Murchison Hospital, the dosing for MDR-TB 
treatment is dependent on patients’ body weight, for example, a patient weighing 
approximately 50kg receives a 2 millilitre dosage (Li & Steyger, 2009). The medical staff 
administer this medication uniformly, i.e. all patients with MDR-TB receive a 6 month 
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injectable course of kanamycin. Thereafter a tablet-form medication is administered for 
two years. The tablets contain ofloxacin, terizidone, ethambutol, pyrazinamide (PZA) and 
ethionamide. The regimen is dependent on the patient’s condition; they will either receive 
a once a day dosage for five consecutive days or a twice a day dosage for three 
consecutive days (Begg & Barclay, 1995; Peloquin et al., 2004).  
KwaZulu-Natal province has the second-largest population in South Africa, 
estimated at 10 449 300 million people in 2009, with approximately 105 people per 
square kilometre. With a total area of 94 361 square kilometres, KwaZulu-Natal is South 
Africa’s third-smallest province, taking up 7.7% of South Africa's land area. It has a 
21.2% population share of the total South African population (Statistics South Africa, 
2009).  Ugu District is considered an area affected by poverty and makes up 8.2% of 
KwaZulu-Natal’s total population, making it a good representation of the South Africa’s 
general rural population (Provincial Decision-Making Enabling, 2005). The above 
mentioned factors, namely good hospital records, high MDR-TB rates and good 
representative population of South Africa, highlight the accessibility and importance of 
conducting the research in this area. 
2.9  Materials and Procedures 
2.9.1. Data capturing 
The researcher was responsible for collecting and reviewing the patient records. 
Prior to data collection taking place, the researcher had to ensure approval for the study 
was obtained from the relevant supervisory authority at the hospital and from the 
University of Witwatersrand Ethical Committee (Medical). A spreadsheet was then used 
to organize the data from the relevant patient files. The following information was 
collected and inserted onto the spread sheet (See Appendix A): 
- Sample code number 
- Age 
- Gender 
- Admission and discharge dates 
- History of hearing loss due to noise exposure, middle ear pathologies or other 
causes for exclusion purposes 
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- Audiological results, including otoscopic examination, tympanograms, Distortion 
Product OAEs and Pure Tone Audiometry (from 250-12 500 Hz) 
- Audiological management, including recommendations, hearing aid evaluation 
and/or fitting of hearing aids 
2.10 Testing Protocol  
The principle behind testing hearing is “to aid in the process of making decisions 
regarding the type and extent of a patient’s hearing loss” (Martin & Clark, 2003, p. 67). 
Therefore, several audiological assessments are needed to achieve the above as no single 
test can provide a clear picture of a patient’s hearing status (Sweetow & Sabes, 2008). At 
the Audiology Department at Murchison Hospital, a standardized audiological protocol 
was used for the monitoring programme. Listed below is the protocol and equipment used 
for initial and monthly follow-up assessments:  
- Case history (case history form) 
- Otoscopic examination (Heine Mini Otoscope and its accessories) 
- Acoustic Immittance (GSI 38 Auto Tymp and its accessories) 
- DPOAEs (Bio-Logic AuDX device and its accessories) 
- Pure Tone audiometry up to 12 500 Hz (Madsen Orbiter 922 clinical audiometer) 
The case history is the beginning of any audiological evaluation. It contains 
pertinent information including medical problems and previous hearing loss (Bess & 
Humes, 2008; Martin & Clark, 2003). In this part of the audiological evaluation, the 
researcher was able review the case histories notes and exclude those patients records 
presenting with any of the exclusion criteria (i.e. history of hearing loss, middle ear 
pathologies and age range) and include those records deemed appropriate by the inclusion 
criteria for the study.  
The otoscopic examination, conducted using a Heine mini otoscope, allowed for 
the audiologist to examine the pinna, outer ear canal and tympanic membrane for any 
foreign bodies or obstructions as well as infection and ear canal collapse (Wall, 1995). 
Occlusion in the outer ear canal may be the cause of a conductive hearing component, 
which was an exclusion criterion in this research project. It also allowed the audiologists 
to choose the correct tympanometer nub size. Selecting the correct nub size allows a 
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hermetic seal to be made with the external auditory meatus, which leads to more accurate 
tympanometry readings being recorded (Jordan & Roland, 2000; Gelfand, 2001).  
At the time of testing, all audiological testing took place in a sound-attenuating 
booth, ensuring valid and reliable results (Gordon, Phillips, Helt, Konrad-Martin, & 
Fausti, 2005). Static acoustic immittance is described as the immittance of the middle ear 
at some “representative” air pressure (Gelfand, 2001). Acoustic immittance is a sensitive 
and objective diagnostic tool that is used to identify the presence of fluid in the middle 
ear, to evaluate Eustachian tube and facial nerve function, to predict audiometric 
findings, to determine the nature of hearing loss, and to assist in diagnosing the site of 
auditory lesion (Bess & Humes, 2008). The GSI 38 Auto Tymp, is a tympanometer that 
was used for this part of the assessment and was particularly useful in determining middle 
ear status of the patients (Margolis & Hunter, 2000), therefore excluding those patient 
records that indicated middle ear pathologies from the study. Immittance audiometry 
includes tympanometry and acoustic reflexes. Standard single frequency tympanometry 
was employed using an 85.5dB SPL tone test set at 226 Hz, by default of the GSI Auto 
Tymp.  Tympanometry measures the mobility and compliance of the tympanic membrane 
by pressurizing the air in the external ear canal. This measurement gives invaluable 
information regarding the condition of the middle-ear structures (Martin & Clarke, 2003; 
Fire, 1995). Basic acoustic reflex testing involves presenting a sufficiently intense sound 
to activate the middle-ear muscles reflex and observing any resulting change in 
immittance, which is usually seen as a decrease in the ear’s static admittance (Gelfand, 
2001). If the reflex is elevated or absent, a conductive hearing loss exists (Gelfand, 2001), 
and thus patient records that presented with these results were excluded from the study. 
The Jerger system (1970) was used to analyse tympanometry results. This system is the 
most common system of classification of tympanograms, and it is a qualitative method 
based on the tympanograms height and peaks (Fowler & Shanks, 2002).  Only patient 
records that presented with Type A tympanograms during their monthly audiological 
follow-ups were considered for this study. A Type A tympanogram indicates normal or a 
sensorineural hearing loss, where all other types indicate other abnormal findings 
(Margolis & Hunter, 2000). 
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OAEs are inaudible, acoustic energy produced by the healthy cochlea and 
recorded in the external auditory canal by a sensitive microphone (Bhagat, 2009). They 
reflect pre-neural activity and are a result of outer hair cell (OHC) motility. OAE testing 
is a measurement of function, (i.e. OHC function) not of hearing. DPOAEs are responses 
generated when the cochlea is stimulated simultaneously by two closely paced pure tone 
frequencies. Therefore DPOAEs occur as a result of the interaction between the two 
primary tones. DPOAEs are good clinical tools because the frequency at which the 
response occurs is predicted exactly by the frequency of the primary tones (Hall, 2000). 
DPOAE amplitude is not influenced by gender, race, body temperature and/or position or 
sedatives/anaesthetics (Schmuziger, Lodwig & Probst, 2006). The Bio-Logic AuDX 
device was used in the Murchison Hospital to perform DPOAE screening measures. The 
OAE audiometer is an automatic device that can be used for diagnostic and screening 
purposes and provides objective evaluation but subjective interpretation of its data and 
test results (Schmuziger et al., 2006). The AuDX is the first hand-held automated OAE 
system and it does not require a connection to a computer. The user can customize test 
protocols and programme the device to perform a desired function i.e. ototoxic hearing-
loss screening. The device was programmed as a diagnostic screener, as per the 
manufacturer’s protocol, as it indicates a pass/refer criteria for each frequency tested. 
Though this may still be a screening protocol and not a full diagnostic measure, the 
display of pass/refer ensures consistent interpretation of results between different testers 
and from patient to patient and reduces user error in applying the pass/refer criteria (Hall, 
2000). This was particularly useful in the clinical setting at Murchison Hospital, as 
testing was performed monthly on each patient and by several audiologists.  For 
statistical purposes, an overall pass/refer criterion was set for each DPOAE repeated 
measure done at each frequency. This was based on a pass for more than 50% of the high 
frequencies (4000-8000 Hz), as literature supports (Campbell, 2007; Duggal & Sarkar, 
2007; Konrad-Martin et al., 2005) that ototoxic hearing loss is characterized by high-
frequency hearing loss. Furthermore, literature suggested that DPOAE readings should be 
present for at least half of the tested frequencies in order for a pass criterion to be granted 
(Schmuziger et al., 2006).  
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Some of the AuDX features that made it an appropriate measurement include that 
one ear probe with multiple nub sizes can be used for performing DPOAE, it is portable, 
and has compact hardware. The AuDX also has a measurement-based stopping rule. This 
rule is based on the set of criteria that determines the duration of averaging during OAE 
testing (Hall, 2000). This is a far superior method than the fixed averaging time method, 
as it helps to obtain an optimal response measurement in the shortest amount of time 
possible for a test. The device automatically stops averaging once an online assessment of 
the OAE and noise floor amplitude is complete and sufficient information is obtained 
according to the devices’ algorithm. The AuDX has an automatic, unique, proprietary 
method for reducing effects of noise on DPOAE readings, therefore improving testing 
performance in noisy environments. The method by which the noise floor is measured is: 
by calculating the noise floor amplitude by averaging the signal amplitude present in four 
50 Hz frequency bins surrounding the DP frequency bin. The AuDX also has an in-the-
ear-calibration process that automatically adjusts the stimulus to its target level according 
to the ear canal size. The AuDX also displays if a probe fit was not achieved and will not 
continue testing unless a fit is achieved, ensuring reliable test results are obtained (Hall, 
2000). All these features and methods are designed to optimize testing protocols and 
result in accurate and reliable DPOAE readings.  
OAEs are valuable for ototoxic monitoring as they are site- and frequency-
specific for cochlear dysfunction and ototoxic agents exert their effect on OHC’s. The 
recording is electrophysiological and objective and results can be obtained from patients 
who are medically unable to perform behavioural audiometry (Hall, 2000). OAEs provide 
valuable and sensitive information on cochlear auditory function and can make an 
important and unique contribution to early detection of cochlear impairment, as ototoxic 
drugs affect the outer hair cells of the cochlea (Hall, 2000).  
Research suggests that OAEs are sensitive to pre-clinical changes in OHC 
functioning, therefore detecting high-frequency changes earlier than conventional 
behavioural audiometry (Konrad-Martin et al., 2005). An advantage of using DPOAEs in 
this study was because DPOAEs are said to have higher sensitivity to ototoxic damage 
than Transient Evoked OAEs (Konrad-Martin et al., 2005).  The limitation with OAEs is 
their unreliability to predict pure-tone thresholds and when calibrating the OAE 
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equipment errors are often made above 3000 Hz. Also, DPOAE levels only correlate with 
pure-tone thresholds up to about 55dB SPL (Konrad-Martin et al., 2005). The limitation 
in this study was that OAE testing was not conducted at frequencies over 8000 Hz; but at 
250, 750, 1000, 2000, 3000, 4000, 6000 and 8000 Hz i.e. Eight frequencies for both left 
and right ears at each audiological session. There have been studies to show that 
DPOAEs can detect changes before conventional audiometry following ototoxic 
exposure; however some other studies suggest that no DPOAE changes occur in early 
exposure (Bhagat, 2009), thus raising the importance of using a combination of 
audiological investigations (Sweetow & Sabes 2008), as was observed in this record 
review.  
Pure tone audiometry had been conducted on each patient at each monthly 
interval of monitoring. Its clinical use was to determine the degree, type and 
configuration of hearing loss (Roeser & Clark, 2007). However in this study it was also 
used to monitor any audiological changes seen over time, especially as the higher 
frequencies appear to be more susceptible to external factors such as the effects of 
medication (Harrell, 2002). It is a behavioural assessment that involves the central and 
peripheral auditory systems (Stach, 2003) and is dependent on the integrity of inner hair 
cells and the auditory nervous system (Bhagat, 2009). Pure tone thresholds specify the 
softest audible sound to a patient (i.e. hearing sensitivity) at least 50% of the time (Bess 
& Humes, 2008) across a range of frequencies. These usually include 250 Hz, 500 Hz, 
1000 Hz, 2000 Hz, 4000 Hz, and 8000 Hz (Martin & Clarke, 2003). However, as 
mentioned previously, HFA is a suggested method for monitoring the effects of ototoxic 
medication (Harrell, 2002).  
A Madsen Orbiter 922 clinical audiometer that could conduct high frequency 
testing was used to obtain behavioural thresholds in the right and left ear of each patient. 
The modified Hughson-Westlake technique (Carhart & Jerger, 1959) was used, in 
conjunction with the use of Welch Allan standard TDH-39 circumaural headphones, to 
determined pure tone air conduction thresholds. The Hughson-Westlake technique was 
established to decrease the influences of perseveration, adaption and inhibition. The tone 
is presented in a pulse-type manner; if a response is obtained then the intensity is 
decreased by 10dB and then increased by 5dB until a response is made again (Roeser, 
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Buckley & Stickney, 2000). If there is a loss in hearing sensitivity, pure tone air 
conduction audiometry specifies the degree of loss (Martin & Clarke, 2003). Ototoxic 
hearing loss is characterized by significant drop in the high frequencies, following 
considerable doses of ototoxic medication. Inter-octave frequency testing was only 
performed when a difference of 20dB or more was evident in the thresholds at adjacent 
octaves (Harrell, 2002) but was not included in the statistical analysis, as the need to 
conduct inter-octave testing was only performed on a few patients. According to Stach 
(2003) ‘high frequencies’ is a non-specific term referring to frequencies above 
approximately 2000 Hz; a high-frequency audiometer is described as an audiometer with 
a frequency range extending beyond 8000 Hz. It is further said that HFA has a larger 
deviation than standard audiometry ranges and this variability is more evident in older 
age groups. Research conducted by Hallmo, Sundby and Mair (1994) found that over the 
age of 50 years, few participants were able to detect the higher-frequency tones which 
suggests that as age increases the sensitivity for higher-frequency tones appears to 
decrease (Harrell, 2002). In another study by Wiley, Cruickshanks, Nondahl, Tweed, 
Klein and Klein (1998), adults aged 48-92 years old were investigated using ultra HFA. 
They found that hearing sensitivity, for ultra-high frequencies increased with advancing 
age and that males presented with higher thresholds in the frequencies 8000-14 000 Hz 
than females at those frequencies. For the higher frequencies (14 000-20 000 Hz), no 
gender differences were observed in their threshold sensitivity. Regardless of the HFA 
not extending up to 20 000 Hz in this study due to the audiometer limitations, there is 
research that suggests that low frequency distortion occurs when tones at 16 000 Hz are 
presented at high levels (Schmuziger, Patscheke & Probst, 2007). More research indicates 
that intra-participant threshold variability exists for frequencies ranging from 14 000-16 
000 Hz, with 16 000 Hz having the highest variability in repeated thresholds 
(Schmuziger, Probst & Smurzynski, 2004). Therefore had higher frequencies (14 000-20 
00 Hz) been included in the audiological assessment of the patients’, the reliability of 
these thresholds would have been questionable.  
 HFA is said to have good test-re-test reliability and low false-positive rates 
(Konrad-Martin et al., 2005; Frank, 2001; Gordon et al., 2005), thus making it ideal for 
reliable and sensitive ototoxic evaluation. Serial monitoring with intra-subject reliability 
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is said to be the most reliable method for detecting ototoxic hearing loss. Test-retest HF 
thresholds need to be within ± 10dB range in order for serial ototoxic monitoring to be an 
effective and reliable tool (Gordon et al., 2005).  This study achieves this reliability by 
containing test-retest thresholds, especially for the HF, that are within ± 10dB range of 
each other; and test-retest thresholds for frequencies below 8k, that are within ± 5dB 
range of each other. Furthermore, testing was completed in a sound-attenuated booth, 
ensuring reliability across the frequencies (Gordon et al., 2005). It is highly 
recommended that HFA not be done in isolation, due to the lack of hearing threshold shift 
normative data. Therefore, as recommended by research (Schmuziger et al., 2004; 
Sweetow & Sabes, 2008), HFA rather be done in conjunction with other audiological 
investigations and with conventional PTA, as done in this study.   
According to ASHA’s 1994 guidelines, specific criteria exist for defining ototoxic 
hearing loss. The change in hearing sensitivity must always relate to baseline measures 
and must always be confirmed by repeated testing. The specific criteria are defined as (1) 
a 20dB decrease at any one test frequency, (2) a 10 dB decrease at any two adjacent test 
frequencies, or (3) a loss of response at three consecutive test frequencies where 
responses were previously obtained. This last criterion refers specifically to the highest 
frequencies tested, where earlier responses are measured close to the limits of audiometer 
and later responses cannot be obtained at the limits of the audiometer. It is highly 
recommended that change be confirmed with repeat testing. Specific criteria for defining 
ototoxic hearing loss have been controversial and varied (Simpson, Schwan, & 
Rintelmann, 1992); therefore the ASHA criteria were used as they have been well-
researched and ASHA strives for uniformity in audiological practices (ASHA, 1994; 
Schmuziger et al., 2004). The criteria are conservative as “the occasional false-positive 
identification is preferable to methods that may delay detection of the ototoxic process” 
(ASHA, 1994, pp. 5). Shifts seen at adjacent test frequencies and decreases seen on 
repeated measures reflect valid changes in threshold sensitivity (ASHA, 1994). A shift in 
threshold, relative to baseline measures, seen at least twice indicates a true shift. 
Consequently, the three criteria set by ASHA (1994), were used to indicate ototoxic 
hearing loss for each participant record, at each baseline and the four follow-up 
audiometry evaluations.  
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The hospital where the data was reviewed operates under strict infection-control 
procedures. During all patient contact for hearing testing and subsequent treatment, the 
audiologist employed effective infection control procedures, specifically as these patients 
were already very ill and contagious and harmful organisms could be easily passed from 
person to person (Martin & Clarke, 2003). All patients who were found to have abnormal 
conductive hearing impairments were referred for appropriate medical treatment.  
The purpose of audiological monitoring is for early identification of ototoxic 
hearing loss. This allows professionals and patients to make informed decisions about 
treatment options, drug regimens can be adjusted, patients can be counseled and be 
prepared for living with a hearing loss and rehabilitation can be planned and implemented 
(Konrad-Martin et al., 2005). There are published guidelines about the audiological 
management of patients treated with ototoxic medications (ASHA, 1994; 2004; 
Campbell, 2007; Fausti et al., 1999) but none are published for the South African 
population. These previously mentioned guidelines suggest that basic audiological 
evaluation be conducted with the inclusion of ototoxic-specific measures such as HFA 
(>8000 Hz) and OAEs. The inclusion of objective measures such as OAEs and/or central 
auditory monitoring is useful given the medical condition of such patients undergoing 
this treatment. Furthermore, such measures that can detect changes in the high 
frequencies, before speech related frequencies are affected, should be incorporated in the 
audiological monitoring given the nature of the hearing loss caused by ototoxic agents 
(Konrad-Martin et al., 2005). Bhagat (2009) strongly suggests that the inclusion and 
refinement of DPOAE test protocols in detecting cochlear damage can enhance hearing 
conservation of patients exposed to ototoxic medications, as DPOAE’s accurately reflect 
cochlear status, even at early exposure instances. ASHA (1994) has highlighted the need 
for baseline audiological evaluations before the commencement of treatment and 
consecutive, periodic monitoring thereafter. 
2.11  Data Analysis and Statistical Procedures 
The study made use of descriptive and inferential statistics. The total sample 
consists of 68 patient records, with each patient being seen over five sessions (i.e. 340 
result readings) and each ear yielding individual results (i.e. 680 result readings). 
Descriptive statistics form the basis of quantitative analysis, as they provide simple 
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summaries about the sample and the measures and allow the researcher to provide basic 
features of these data (Trochim, 2006). Furthermore, the researcher could develop trends 
or relationships among variables and allowed possible group differences to be observed 
(Schiavetti & Metz, 2002). “Research of this type provides an empirical picture of what 
was observed at one time or of observed changes over a period of time, without the 
manipulation of independent variables by the researcher” (Schiavetti & Metz, 2002, p. 
46).  The independent variables in the current study that were reviewed by the researcher 
were as follows: age, gender, ear performance and audiological testing results over time. 
Descriptive statistics were used to describe the demographics of the sample and 
the possible audiological changes in the total sample including otoscopic examination, 
tympanograms, DPOAEs and PTA thresholds. For DPOAEs results, the total patient 
records indicated that DPOAE readings were taken for both ears at all five audiological 
sessions across eight frequencies; therefore for DPOAEs n=1088. DPOAEs were 
analysed descriptively as left ear, then right ear, then both ears together for better 
comparison to the remaining audiological tests used. Whereas, for PTA results, mean 
thresholds were used to clinically describe the results for left ear, then right ear, then both 
ears at all five audiological sessions across nine frequencies; therefore n=68. Clinical 
reference to the classification system of hearing loss (Table 3) by Silman and Silverman 
(1991) is used in the descriptive analysis of PTA thresholds, to show significant PTA 
threshold changes in this group of adults on MDR-TB treatment. 
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Table 3  
Classification of hearing loss  
 
Classification of Hearing Loss (Silman & Silverman, 1991) 
Decibels (dB)  Hearing severity  
26 Normal 
26-40 Mild  
41-55 Moderate 
56-70 Moderate-Severe 
71-90 Severe 
90 Profound 
 
The use of inferential statistics is a more mathematical method that allows for 
inferences to be made beyond the immediate data. Research outcomes can be easily 
generalized (Trochim, 2006) using probability theory and assists the researcher to test a 
particular hypothesis. It is also concerned with the precision and reliability of the 
inferences it helps depict (Fife-Shaw, 2002). For this reason descriptive and inferential 
statistics were used in this study. 
Specific inferential statistical analysis methods included a mixed model analysis 
of covariance (ANCOVA) and logistical regressions were used to test the relationship 
between audiological findings (PTA and DPOAE) and the independent variables: age, 
gender, ear and time, respectively.  According to Schiavetti and Metz (2002, p. 342), this 
“allows the researcher to test (the) main effect of each independent variable” and the 
interaction between the variables. That is, the study would like to investigate whether 
age, gender, ear and time have a significant impact on DPOAE and PTA results in adults 
on long-term MDR-TB medication. Hence, age, gender, ear and time are predictors or 
independent variables, and DPOAE and PTA are predicted or response variables. To 
examine the relationship between DPOAE and the four factors, a logistic regression was 
carried out. Logistical regression is a multiple regression where the response variable is 
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dichotomous (nominal variable with two categories), like DPOAE, with refer and pass. 
As PTA results are in interval scale, and factors are in continuous scale (age) and nominal 
scale (gender, ear and time), analysis of covariance (ANCOVA) was carried out to 
examine the relationship between pure tone results and the four factors. ANCOVA uses 
categorical and continuous predictor variables; it is a joining of the regression model with 
the analysis of variance. The objective of an analysis of covariance is to compare the 
means of the response variable in the different levels of categorical predictor variables, 
after adjusting for differences due to the covariate (continuous predictor variable) 
(Armitage, Berry & Matthews, 2009). The null hypothesis stated that there are 
audiological changes in adults receiving long-term MDR-TB treatment. The alternate 
hypothesis stated that there are no audiological changes in adults receiving long-term 
MDR-TB treatment. To statistically test this hypothesis, calculated p-values were 
considered statistically significant at or above an alpha value of 0.05. This meant that 
there would be a 95% confidence level that results were not due to chance (Howell, 2008) 
and all the hypotheses were tested at 5% significant level. Thus, null hypotheses are 
rejected if p-values are less than 0.05.  Statistical procedures were performed by a 
statistician. 
Logistical regression is used for prediction of occurrence of an event (Armitage, 
et al., 2009). The logistical regression expresses the relationship between the logarithm of 
Odds of an event (pass or refer) and the predictors (age, gender, ear and time) in the 
following model: 
                                 Log (Odds) = β0+β1*x1+β2*x2+β3*x3+β4*x4 or  
                             Odds = Exponential (β0+β1*x1+β2*x2+β3*x3+β4*x4) 
Odds are defined as the ratios of probability of pass over the probability of refer. 
β0 is the intercept, the value of the log (Odds) without any predictor variables; β1, β2, β3 
and β4 are parameter estimates of predictors x1, x2, x3 and x4 respectively (x1, x2, x3 and 
x4 represent age, gender, ear and time respectively). 
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Table 4  
Creation of dummy variables 
 
Categorical Variables Codings  
 
 
 Parameter coding 
(1) (2) (3) (4) 
Time First month 1 0 0 0 
Second month 0 1 0 0 
Third month 0 0 1 0 
Fourth month 0 0 0 1 
Fifth month 0 0 0 0 
Ear Left 1    
Right 0    
Gender Female 1    
Male 0    
Dependent variable coding 
 DPOAE Refer 0    
Pass 1    
 
Table 4 indicates the creation of dummy variables or indicator variables. From 
variable time, four dummy variables (1), (2), (3) and (4) are created; dummy variables are 
binary variables with the value of 0 or 1. The last category, i.e. the fifth month, is 
considered as a reference category; that is, the absence of the first four implies the 
presence of the fifth month. From ear and gender, only one binary variable is created, 
respectively. A binary variable with a value of 0 will cause that variable's coefficient to 
disappear and a binary with a value of 1 will cause the coefficient to operate as an 
additional intercept in a regression model (Sharma & Garavaglia, 1998).  Thus each time 
the dummy variable occurs as the substitute variable, it assumes the value of 1 in the 
regression (Gelman & Hill, 2007). Dummy variable or indicator variables were assigned 
to certain qualitative variables such as gender and ear, as seen in table 4 i.e. left ears has 
been assigned the value of 1 and right ears the value of 0; males has been assigned 0 and 
females has been assigned the value of 1. These binary variables are assigned the value of 
0 or 1 to indicate the absence or presence of a categorical effect (i.e. time) that may be 
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expected to shift the outcome effects (Draper & Smith, 1998). The dummy variables act 
as substitute variables for qualitative variables in regression models such as this one, 
where dependant variables can be influenced by qualitative variables such as ear and 
gender and quantitative variables such as time. Dummy variables have been used as they 
are often used in regression models and in time analyses such as this study (Gelman & 
Hill, 2007). 
Table 5  
Test of Model Signification 
 
Hosmer and Lemeshow Test  
Step Chi-square df P-value 
1 25.111 8 .046 
 
The Hosmer–Lemeshow test was also used, as it is a statistical test of the 
effectiveness and beneficial match for a logistic regression model. The test assesses 
whether or not the observed event rates match expected event rates in sub-samples of the 
total sample. The Hosmer–Lemeshow test specifically identifies sub-samples as the 
deciles of matched risk values; that is, one of the values of the variable divided the 
distribution of the variable into sub-samples of equal occurrences. Models for which 
expected and observed event rates in sub-samples are similar and are referred to as well-
calibrated (Allan, 2002). Table 5 indicates the results of the signification of the model. 
That is, it is important to investigate whether the model with the independent variables 
included, is significantly better than a model with just intercept variables. So, the null 
hypothesis states: 
                   H0: β1= β2= β3= β4=0  
and the alternative hypothesis states: 
                   H1: at least one of the betas (β) is different from zero. 
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The p-value is < 0.046; hence the conclusion is the rejection of the null 
hypothesis. That is, the model with independent variables is significant. 
Graphical and tabular representation were also used, as graphs and tables are a 
valuable and organized manner in which to present data and results, as they show the 
overall contour of the distribution (Schiavetti & Metz, 2002, p. 163.). 
2.12 Reliability and Validity 
In order to increase the reliability and validity of the study, certain conditions 
were considered when utilizing the data available for the study. Conditions included well-
documented patient records, calibration records (See Appendices G-K) and measurement 
methods (Schiavetti & Metz, 2002). The researcher reviewed and collected the files 
personally to ensure constancy in the study. 
The files, which were reviewed, were from an established audiology department 
at Murchison District Hospital. When the data were collected, the audiological team 
consisted of a qualified senior audiologist and two community service speech therapists 
and audiologists. The protocols in the department used existing and established protocols 
and followed the recommended programme in order to effectively monitor patients on 
MDR-TB treatment monthly. These tests were selected based on their appropriateness 
and validity in testing for ototoxicity (Khoza-Shangase et al., 2009). HFA (>8000 Hz) 
has been suggested as a method for monitoring the effects of ototoxic medication, as the 
higher frequencies appear to be more susceptible to external factors such as the effects of 
medication (Harrell, 2002). In accordance with Murchison Hospital’s regimen protocol, 
the patients were on uniform drug regimens where either dosing routines were used 
depending on the patient’s condition. This in turn attempts to reduce the variability and 
improves the reliability of the current study. Previous literature confirmed that the use of 
two different weekly dosing routines made no difference in the development of ototoxic 
hearing loss (Begg & Barclay, 1995; Peloquin et al., 2004). Duggal and Sarkar (2007), 
suggested drug treatment start immediately due to the high infection rate of MDR-TB. 
Therefore, patients admitted to the MDR-TB unit began drug treatment immediately and 
were referred to the audiology department within one week of admission or on admission. 
ASHA (1994) suggests that audiological testing should occur prior to or within 72 hours 
of drug commencement. Despite not having baseline measures prior to drug 
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commencement, the inclusion criteria were set as a means of controlling for previous 
hearing loss of any kind. The audiological investigations used in this study were repeated 
measures that the patients routinely underwent. Due to this routine testing, false-positives 
were reduced, thus improving the reliability of the study.  Repeated measurements are a 
useful feature to have when it is unfeasible for the investigator to select a random or large 
sample (Schiavetti & Metz, 2002). Furthermore, the patient record information was 
considered to be reliable since the information was obtained from medical and 
audiological records and not from patient-self reports. Self-reports run the risk of 
dishonesty, misunderstanding of the research protocols and false-positives by the 
participants (Turkkan, 2000).  External validity relates to the ability of the outcomes of 
the study to be generalized to a larger population or other studies (Trochim, 2006). 
Generalization is improved with direct replication, in this case availability of repeated 
measurements on the same participants. In this study, the sample was representative of 
the population in the area, therefore strengthening external validity (Trochim, 2006).  
2.13 Ethical Considerations 
According to the Health Professionals Council of South Africa (HPCSA) 
Professional Guidelines (2008), in some instances research projects may depend on using 
samples and it is not always possible to contact patients to seek their consent. 
Furthermore, many of the MDR-TB patients had passed away given the seriousness of 
the illness. Permission was granted from the supervisory authorities of Murchison 
Hospital, namely the medical manager, the rehabilitation supervisor and the senior 
audiologist of the audiology department, for use of record data and any additional 
information that may be needed. Data were collected under the following conditions: 
1. Ethical approval for the study was obtained from the relevant supervisory 
authority and from the University of Witwatersrand Ethical Committee (Medical).  
2. Hospital approval from the medical manager of Murchison Hospital. 
3. Departmental approval from the supervisor of the audiology department at 
Murchison Hospital.  
4. If the research proposal had been altered, prior approval would have been 
obtained from management. 
5. The results of the proposed research will be made accessible to the hospital.  
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(See Appendix B and C) 
According to Chabon and Morris (2005), ethics is a set of moral principles that 
govern or influence decisions and conduct on a coherent and consistent basis; in this case 
research conducted by an audiologist. Ethical responsibilities described by professional 
medical bodies include “continuing education, research, and scientific advancements so 
that the quality of care available and the efficacy and efficiency with which resources are 
used in that care can be improved over time” (Chabon & Morris, 2005, p. 6.). Therefore, 
the following ethical considerations were considered during the proposed research.  
- Beneficence and Non-maleficence: acting in the best interest of the patients and 
doing no harm to them (ASHA, 2010). This principle was upheld as no harm or 
risk came to pass for patients whose files were reviewed. 
- Confidentiality: was maintained as the names of those patient records used were 
not published while anonymising data further ensures confidentiality (Irwin, 
Pannbacker, Powell & Vekovious, 2007; Trochim, 2006) by supplying the patient 
records that were reviewed with numbers as a research coding system.   
- Justice: all participant data were treated in an “impartial, fair and just manner” 
(HPCSA, 2008, p. 3.). 
- Professional competence and the Community: the researcher attempted to 
maintain a high level of professionalism during the collection and revision of the 
data. Furthermore, the research will be made available to the community at hand, 
so as to contribute to the improvement of society (HPCSA, 2008, p. 9.) and the 
researcher has considered the long-term implications of the study (Wisker, 2001) 
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CHAPTER THREE 
RESULTS 
 
3.1  Introduction 
The outcomes of the investigation into the hearing function of adults on long-term 
MDR-TB treatment from a hospital in KwaZulu-Natal are presented in this chapter in 
accordance with the primary and secondary aims of the study. To achieve the study’s 
aims and test the hypotheses, statistical analyses were carried out using the Statistical 
Packages for Social Sciences (SPSS) version 16 (2012). The main aim, sub aims and the 
hypothesis were answered using both descriptive statistics (means and standard 
deviations) and inferential statistics. Regression analysis and ANCOVA was used to test 
the relationships between audiological findings on HFPTA and DPOAEs, and age, 
gender, ear and time. The data will be summarised and presented before the discussion of 
the results.  In this analysis, calculated p-values were considered statistically significant 
at or above an alpha value of 0.05. This meant that there would be a 95% confidence 
level that results were not due to chance (Howell, 2008).  
3.2  Descriptive statistics 
3.2.1  Demographics 
The study comprised of 68 patient records, of which all records indicated that 
patients were between the ages of 18.00 and 49.11 years of age. The sample records 
included 33 males (49%) and 35 females (51%), with a mean age of 33.4 years. All 
patients were admitted to Murchison Hospital’s MDR-TB unit and seen monthly at the 
hospital’s audiology department.   
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Figure 1  
Distribution of the gender of the sample  
 
Figure 1 shows the percentages of males and females used in the study. It can be 
seen from the above figure that the male: female distribution is fairly balanced i.e. 49% 
vs. 51%. The researcher used a non-probability convenience sampling technique, and so 
was limited to the availability of patient files, be that male or female files.  
3.2.2 Results of the audiological changes reviewed in the total sample 
The primary aim of investigating for possible audiological changes from 
commencement of MDR-TB treatment over a five-month period is explained in 
accordance with the audiological test protocol used at Murchison Hospital from initial 
assessment through to the final assessment.  This information was gathered by reviewing 
all audiological investigations that the patients underwent from initial audiological 
assessment until the fifth audiological assessment. All information pertinent to this study 
was obtained from patient files.  
i. Otoscopic Examination and Tympanograms  
In accordance with the inclusion and exclusion criteria set out for this study, only 
patient records with obstruction-free ear canals and Type A tympanograms at each 
audiological investigation, were considered for this study. Other patient files were 
considered, but found to be unsuitable as the records revealed obstructed ear canals and 
therefore incomplete tympanograms. According to the records used in this study, all 68 
51% 
49% 
Distribution of the gender of participants (N=68)  
Female Male 
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patient records revealed obstruction-free ear canals and Type A tympanograms at all five 
audiological sessions, including the baseline audiological investigation. The results for 
otoscopic examination and tympanograms will be examined further in the discussion 
chapter.   
ii. DPOAEs 
DPOAEs were conducted on all patients (N=68) at initial audiological assessment 
and at each follow-up session. Each patient had readings taken for their left and right ear 
i.e. 136 readings per patient; and at each frequency (250-8000 Hz). Therefore, within the 
total sample, 1088 DPOAE readings were collected from the records, with 544 readings 
per ear in the total sample. The results for DPOAEs at each audiological session will be 
descriptively discussed in this section and related to statistical analysis, beginning with 
initial DPOAE readings at session one, followed by DPOAE readings at sessions two-
four, and lastly the fifth and final DPOAE reading at session five.  The researcher was 
concerned with the number of ‘refer’ readings, as this indicates a dysfunction with 
hearing function. The results will be discussed in the subsequent chapter.  
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Figure 2  
Number of pass/refer left ear DPOAE readings at session one  
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Figure 3 
Number of pass/refer right ear DPOAE readings at session one  
 
33 
40 
39 
44 
46 
26 
21 
22 
35 
28 
29 
24 
22 
42 
47 
46 
0 10 20 30 40 50 
250 
750 
1000 
2000 
3000 
4000 
6000 
8000 
Number of pass/refer 
Fr
e
q
u
e
n
cy
 r
an
ge
 
Number of pass/refer right ear DPOAE readings for session one 
(n=544) 
Pass 
Refer 
 49 
 
 
Figure 4  
Number of total pass/refer DPOAE readings at session one  
 
Figures 2, 3 and 4 depict the number of pass/refer readings for DPOAEs at the 
initial audiological investigation. Figure 2 depicts the number of pass/refer readings for 
all the left ears across the DPOAE frequency ranges that were reviewed from the total 
sample (n=544); and Figure 3 depicts the number of pass/refer readings for all the right 
ears across the DPOAE frequency ranges that were reviewed from the total sample 
(n=544). Whereas, Figure 4 depicts both left and right ear DPOAE readings for the total 
sample (n=1088). The number of pass/refer for the left ear compared to the right ear are 
very similar across the DPOAE frequency range. At 4000 Hz; the number of left ear refer 
readings are 34 (50%) and the number of right ear refer readings are 42 (61.76%) 
respectively. For the combined ears and total DPOAE readings at the initial session; at 
the lower and mid frequency range i.e. 250–3000 Hz, the number of pass readings is 
higher than the refer readings for the total sample reviewed; nevertheless the numbers 
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indicate that the sample does show a considerable number of refer readings at the lower 
frequencies. From frequency 4000-8000 Hz, the number of pass readings decreases and 
there is a much higher number of refer readings at session one. On average, at session 
one, the mean average of the total number of pass readings was 33.88 compared to the 
total number of refer readings, at 34.13  
Sessions two, three and four, took place whilst the participants were midway in 
their treatment for MDR-TB whilst at Murchison Hospital. 
 
 
Figure 5  
Number of pass/refer left ear DPOAE readings at session two  
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Figure 6  
Number of pass/refer right ear DPOAE readings at session two  
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Figure 7 
Number of total pass/refer DPOAE readings at session two  
 
At session two, the DPOAE readings for left and right ears are comparably the 
same across the frequency range, as seen in Figure 5 and 6. On average, at session two, 
the mean average of the number of pass readings was 32.63 compared to the number of 
refer readings, at 35.38. Therefore, at session two, the overall number of refer readings 
exceeds the number of pass readings (Figure 7).  
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Figure 8 
Number of pass/refer left ear DPOAE readings at session three  
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Figure 9 
Number of pass/refer right ear DPOAE readings at session three  
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Figure 10 
Number of total pass/refer DPOAE readings at session three  
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Figure 11  
Number of pass/refer left ear DPOAE readings at session four  
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Figure 12  
Number of pass/refer right ear DPOAE readings at session four  
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Figure 13  
Number of total pass/refer DPOAE readings at session four  
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Considering the total pass/refer DPOAE readings for the second, third and fourth 
sessions i.e. Figures 7, 10 and 13; numerically, from frequencies 250-3000 Hz there 
appears to be a lack of consistency with regards to specific frequencies yielding a higher 
number of passes or a higher number of refers at each subsequent session. The readings 
shift from higher/lower referral rates to higher/lower pass rates at each frequency and at 
each subsequent session. Whereas at 4000-8000 Hz, the trend remains more constant, 
with remarkably lower pass numbers than refer numbers. This trend is in agreement with 
literature that supports DPOAEs as being sensitive to changes in hair cell function at 
higher frequencies (Hall, 2000).  
 
 
Figure 14  
Number of pass/refer left ear DPOAE readings at session five  
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Figure 15  
Number of pass/refer right ear DPOAE readings at session five  
 
Only one large numerical difference between left and right ear DPOAE readings 
exists at session five; and that is at 4000 Hz (Figure 14 and 15). The left ear readings at 
4000 Hz indicates 54 (79.41%) refer readings compared to 44 (64.71%) refer readings for 
the right ears. Whereas, across the other frequencies, little numerical differences between 
left and right ear DPOAE readings exists for the final audiological session.  
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Figure 16  
Number of total pass/refer DPOAE readings at session five  
 
The total results of the fifth session of DPOAE assessments are depicted in Figure 
16. The graph clearly shows the large number of refer readings at 250, 4000, 6000 and 
8000 Hz. The low and mid frequency range again show a mixed number of refer and pass 
readings. In the total (i.e. combined left and right) number of pass/refer readings at 
session five in a group of adults on long-term MDR-TB treatment the refer readings far 
exceed the pass readings with mean averages of 25.38 pass and 42.63 refer readings. 
Therefore, at the fifth session of DPOAE screening in this group of adults on long-term 
MDR-TB treatment, the overall number of refer readings far exceed the number of pass 
readings on DPAOE results across all the tested frequencies.   
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Table 6 
Parameter estimates and Odds of DPOAEs for time and ear effect 
 
  Parameters S.E. Wald df P-
value 
Exp(B) 95.0% C.I.for 
EXP(B) 
(B) Lower Upper 
Ear(1) -0.03 0.22 0.02 1 0.88 0.97 0.63 1.48 
Time     7.73 4 0.01       
Session 1 0.93 0.38 6.01 1 0.01 2.54 1.21 5.36 
Session 2 0.93 0.38 6.01 1 0.01 2.54 1.21 5.36 
Session 3 0.83 0.38 4.65 1 0.03 2.29 1.08 4.87 
Session 4 0.60 0.39 2.31 1 0.13 1.82 0.84 3.95 
*key:  S.E.-standard error; df-degrees of freedom; C.I.-confidence interval 
 
On regression analysis of the parameter odds estimate for DPOAEs (Table 6), the 
effect of time on DPOAE changes was statistically significant (p<0.05) for sessions one 
to three. Whereas, these changes were not significant (p=0.9) for ear difference. Whereas, 
the Parameter estimates of odds of passing the DPOAE screening at monthly sessions are 
2.54 times higher in first month (session one), than in the reference time (session five). 
Similar interpretation is applicable for the second and third session, where the Odds of 
passing the DPOAE was 2.25 and 2.29 higher in session two and session three 
respectively. 
Therefore, at all five DPOAE screening sessions in this group of adults on long-
term MDR-TB treatment, the overall number of refer readings far exceed the number of 
pass readings; DPOAE changes are significantly affected by time whereas, ear difference 
has little effect on DPAOE results across all the frequencies tested. 
iii. Pure Tone Audiometry  
Pure Tone Audiometry was conducted on all 68 participants, as per their 
audiological records. PTA was conducted as part of the audiological investigations and 
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was conducted monthly over a five-month period.  PTA included conventional frequency 
range as well as high-frequency testing at 10 000 Hz and 12 500 Hz. For hearing to be 
clinically classified as ‘normal’, PTA thresholds need to be within 0-25 dB across the 
conventional frequency range (Roeser & Clark, 2007). Mean thresholds have been 
analysed by ear difference (left and right) in the total sample and then as the total sample 
(both left and right ears). The PTA results are not set out as initial, middle and final 
sessions, as are the DPOAEs, but are rather represented in line-graphs below, using the 
mean thresholds of each frequency tested at each monthly assessment. Regression 
analysis and analysis of covariance is used to statistically describe the significance of 
PTA threshold changes in the total sample (Table 7). The fifth session is the reference 
category and is therefore absence, as the absence of all the four sessions implies the fifth 
session is most important. The PTA results are then compared to the DPOAE results for 
frequencies and sessions where results showed comparable differences between left and 
right ears and the total sample.  
Table 7 
ANCOVA parameter estimates for ear and time effects for PTA results across all test 
frequencies 
 
Parameter Estimates 
Dependent Variable: Pure Tone Audiometry 
P-values  
  Ear Session 1 Session 2 Session 3 Session 4 
250 Hz 0.17 -4.50 -4.03 -2.7 -0.95 
500 Hz 0.34 0.00 0.00 0.03 0.57 
1000 Hz 0.73 0.00 0.00 0.05 0.34 
2000 Hz 0.53 0.00 0.00 0.00 0.06 
4000 Hz 0.31 0.00 0.00 0.02 0.00 
6000 Hz 0.04 0.00 0.00 0.00 0.04 
8000 Hz 0.79 0.00 0.00 0.00 0.07 
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10 000 Hz 0.70 0.00 0.00 0.00 0.07 
12 500 Hz 0.04 0.00 0.00 0.00 0.27 
 
 
Figure 17 
Mean thresholds of monthly PTA results for the left ear 
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Figure 17 gives a graphical representation of the monthly decline in PTA 
thresholds for the total sample (n=68) for left ears only. From session one through to 
session four, the mean thresholds at 250, 500 and 1000 Hz, were all within the normal 
range of hearing sensitivity for the left ears on the total sample i.e. less than 25 dB. This 
indicates that at these low frequencies, little change in left ear hearing thresholds, over 
four months of receiving treatment for MDR-TB, is evident in this group of adults. 
Whereas, at session five, the left ear thresholds across the entire frequency range are all 
above the 25 dB threshold for normal hearing sensitivity; showing that over an extended 
time period, changes in hearing sensitivity occur across the test frequency range. At 
frequency 2000 Hz, the mean threshold begins to decrease, but only at the fourth session 
of audiological assessment i.e. 28.09 dB. At this frequency, the change in hearing 
sensitivity would clinically be considered a mild hearing loss. However, on analysis of 
variance (Table 7), these changes at 2000 Hz at the fourth session, were found to be 
statistically non-significant as p=0.06. The remaining frequencies show a steady decline 
of PTA thresholds across all five audiological sessions, with the high frequencies, 8000-
12 500 Hz, showing the greatest decline in PTA average and the severest hearing deficit. 
On analysis of variance, the p-values for these frequencies were p<0.05; therefore these 
changes were found to be statistically significant. Therefore the most significant changes 
in left ear hearing function occur at the higher frequencies in this group of adults on 
MDR-TB treatment. 
The PTA results for the left ears from session one, show that clinically from 
frequency 250-8000 Hz, the hearing thresholds remain within the 25 dB normal hearing 
range; at 10 000 Hz the hearing changes from hearing within normal limits to a mild 
hearing loss, and then at the final frequency tested, the hearing slopes to a moderate-
severe hearing loss. On analysis of variance, at 10 000 Hz, these changes were found to 
be statistically non-significant (p=0.07). Session two, begins with hearing within normal 
limits from 250-4000 Hz, and clinically changes from a mild hearing loss at 6000 and 
8000 Hz, to a moderate hearing loss at 10 000 Hz, and finally to a moderate-severe 
hearing loss at 12 500 Hz. Statistically, on analysis of variance, the changes across the 
entire frequency range are considered significant (p<0.05). Clinically, the third session 
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shows changes in hearing sensitivity from hearing thresholds within normal limits from 
250-2000 Hz, to a mild hearing loss at 4000 and 6000 Hz, to a moderate hearing loss at 
8000 Hz and 10 000 Hz; and finally a severe hearing loss at the highest frequency tested. 
Again, on analysis of variance, the changes across the entire frequency range are 
considered significant (p<0.05). Session four shows the same hearing threshold changes 
as session three, but the clinical hearing changes are from hearing within normal limits to 
a mild hearing loss at an earlier frequency, namely 2000 Hz. The hearing severity at the 
highest frequency, 12 500 Hz (83.16 dB), is also severe, but at least 6 dB more severe 
than that at session three (76.91 dB).  On analysis of variance, the changes in hearing 
function at 250, 4000 and 6000 Hz are considered significant (p<0.05). The significant 
changes have already occurred in the earlier sessions of testing, indicating that the 
greatest damage to the auditory system begins early on whilst drug treatment for MDR-
TB begins. The last session of PTA reviews, clinically shows that hearing sensitivity 
ranges from mild to severe hearing loss from 250-12 500 Hz; with analysis of variance 
showing significant changes at 250, 4000 and 6000 Hz (p<0.05). Overall, the graph 
depicts the steady decline in left ear PTA thresholds across the frequency range and 
across the five sessions of audiological testing.  
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Figure 18 
Mean thresholds of monthly PTA results for the right ear 
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Figure 18 gives a graphical representation of the monthly decline in PTA 
thresholds for the total sample (n=68) for right ears only. From session one through to 
session five, the mean thresholds at 250, 500 and 1000 Hz, were all within the normal 
range of hearing sensitivity for the right ears on the total sample; except for 1000 Hz at 
the fifth session falling just outside of the normal hearing value i.e. 26.96 dB. This 
indicates that in the right ear, there is little change in right ear hearing thresholds at these 
low frequencies, over the full five months of receiving treatment for MDR-TB is evident 
in this group of adults. For the remaining frequencies, the mean threshold begins to 
steadily decline over all five audiological sessions, with the high frequencies, 8000-12 
500 Hz, showing the greatest decline in PTA average and the severest hearing deficit. 
The change in hearing sensitivity for the right ear occurs at frequencies greater than 1000 
Hz at sessions three, four and five. More specifically, at session one, clinically hearing is 
within normal limits from 250-8000 Hz. The change in hearing sensitivity occurs at 10 
000 Hz, where clinically the hearing is classified as a mild loss, and at 12 500 Hz, where 
the hearing is now classified as a moderate-severe hearing loss. On analysis of covariance 
(Table 7), these changes are considered statistically significant (p<0.05) at 10 000 Hz and 
12 500 Hz. At session two, the hearing thresholds show changes from 8000 Hz through to 
12 500 Hz; more specifically clinically classified as a mild (8000 Hz), moderate (10 00 
Hz) and moderate-severe hearing loss respectively; and statistically, these changes are 
significant as p<0.05 on the analysis of covariance. The hearing thresholds shift again to 
earlier frequencies at session three, with the hearing loss beginning at 4000 Hz. From 
250-2000 Hz the hearing thresholds are within normal limits; then hearing sensitivity 
changes to a mild hearing loss at 4000 and 6000 Hz, to a moderate hearing loss at 8000 
Hz, to a moderate-severe hearing loss at 10 000 Hz; and finally a severe hearing loss at 
12 500 Hz. The described changes in PTA thresholds are statistically significant (p<0.05) 
on analysis of covariance for session three. Session four shows the same hearing 
threshold changes as session three, but the hearing changes from hearing within normal 
limits to a mild hearing loss at an earlier frequency, 2000 Hz, and then sloping to a severe 
hearing loss at 12 500 Hz. The changes for session four, that are considered significant 
(p<0.05) are at 4000 Hz and 6000 Hz. The remaining changes at the other test 
frequencies are considered non-significant on analysis of covariance for session four. The 
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last session, shows that hearing sensitivity ranges from hearing within normal limits at 
250 and 500 Hz, to a sloping mild to severe hearing loss from 1000-12 500 Hz. Overall, 
the graph depicts the steady decline in right ear PTA thresholds across the frequency 
range and across the five sessions of audiological testing.   
The PTA thresholds between left and right ears show threshold and hearing 
severity differences, at certain sessions and frequencies.  There is little clinical difference 
in the effect PTA thresholds have on hearing loss classification at session one, session 
three and session four for left and right ears. At session two, there is a difference between 
hearing thresholds for left and right ears; the left ear shows earlier signs of thresholds 
changes than the right does i.e. change seen at 6000 Hz in the left ear and change in the 
right ear results begins at 8000 Hz.  The changes are clinically significant at 6000 Hz as 
the left ear presents with a mild hearing loss; and the right is still within normal limits. At 
the fifth session, the difference between left and right PTA threshold changes is that for 
the left ear results, the hearing loss is evident across the entire frequency range i.e. mild 
to severe hearing loss. Whereas, for the right ear results, the hearing loss is only evident 
at 1000 Hz, but slopes from hearing within normal limits to mild to severe hearing loss. 
On analysis of covariance, the ear effect at 6000 Hz and 12 500 Hz is considered 
significant (p<0.05) for PTA thresholds for left and right ears. Clinical changes at 6000 
Hz correspond to the ear effect difference for left and right ears.  
From this comparison (of left and right ear results), it can be said that despite 
hearing changes occurring at earlier and later frequencies at either left and right ear; 
overall in both set of ear results the trend is that for each subsequent session, the change 
in hearing sensitivity occurs at an earlier frequency. Therefore, it is clear that over time 
the hearing deteriorates for both left and right ear PTA threshold results.  
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Figure 19 
Mean thresholds of monthly PTA results  
 
Figure 19 gives a graphical representation of the monthly decline in PTA 
thresholds for the total sample (N=68). From session one through to session four, the 
mean thresholds at 250, 500 and 1000 Hz were all within the normal range of hearing 
sensitivity for adults. Therefore no change in hearing sensitivity was observed at the low 
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frequencies for adults on long-term MDR-TB treatment. The remaining frequencies show 
a steady decline of PTA thresholds across all five audiological sessions, with the highest 
frequency, 12 500 Hz, showing the greatest decline in PTA average and the severest 
hearing deficit. Session one shows clinical changes in hearing sensitivity only at 10 000 
Hz and 12 500 Hz, with mild and moderate-severe hearing losses respectively. On 
analysis of variance, these changes were found to be statistically significant (p<0.05) for 
both 10 000 Hz and 12 500 Hz. At session two the clinical changes in hearing sensitivity 
are seen at an earlier frequency i.e. a mild hearing loss at 4000 Hz, continuing onto a 
moderate-severe hearing loss at 12 500 Hz. The clinical changes in hearing sensitivity at 
session three are very similar to those of session two, except that the hearing loss 
continues onto a severe hearing loss at 12 500 Hz. For both session two and three, the 
changes seen at the respective frequencies described above, are significant on analysis of 
covariance (p<0.05). Session fours’ clinical hearing changes are seen at 2000 Hz, where 
again the hearing loss slopes from mild to severe; however on analysis of covariance at 
this frequency, the changes are found to be non-significant (p>0.05). The final session 
shows that clinically all PTA thresholds range from mild to severe hearing losses across 
all test frequencies. Overall, the graph depicts the steady decline in PTA thresholds 
across the frequency range and across the five sessions of audiological testing.  
Therefore, changes in hearing are evident on PTA (up to 12 500 Hz) for adults on long-
term MDR-TB treatment.  
These changes, in the PTA thresholds for both left and right ears, were found to 
be statistically significant (p<0.05) for all the test frequencies (250-12 500 Hz). The 
statistically significant changes were evident from session one to session three for 
frequencies 250-12 500 Hz; and for session four at 4000-6000 Hz. The most important 
effect of all was the ‘time’ effect, as the study was most focused on the long-term effects 
of the MDR-TB medications on patients’ hearing ability. Therefore, analysis of ‘time’ 
main effect is described below along with ear difference at each audiological test 
frequency for PTA thresholds.  
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Table 8 
ANCOVA Test Results of Between-Subject Effects for Independent Variables (ear and 
time) for PTA frequencies (250-12 500 Hz) in total sample (N=68) 
 
Tests of Between-Subjects Effects 
Dependent Variable: Pure Tone Audiometry 
  250 
Hz 
500 
Hz 
1000 
Hz 
2000 
Hz 
4000 
Hz 
6000 
Hz 
8000 
Hz 
10000 
Hz 
12500 
Hz 
Ear 0.17 0.34 0.73 0.53 0.31 0.04 0.79 0.70 0.04 
Time 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
 
Table 8 is a summary of the ANCOVA analysis of between-subjects results for 
the variables of ear and time in the total sample across the PTA frequencies. In the 
ANCOVA analysis, the interaction effects for the variable of time had p-values of < 0.05 
across all the PTA test frequencies. Therefore the independent variable of time is 
significantly different from zero at all frequencies tested. Therefore the main hypothesis 
is rejected and the interaction effects of time are significant in this study. Whereas, the 
interaction effects for the variable of ear difference has p-values > 0.05 across the PTA 
test frequencies, except for one interaction effect at 12 500 Hz, which has a p-value of 
0.04 for ear difference effect. Therefore for all the other ear interactions across the PTA 
frequencies, the hypothesis is accepted and the interaction effects of ear difference are 
non-significant.  
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Table 9 
ANCOVA parameter estimates of time for PTA across all frequencies  
 
Dependent Variable: Pure Tone Audiometry  
Parameter Estimates of Time 
  Session 1 Session 2 Session 3 Session 4  
250 Hz -11.01 -9.85 -6.62 -2.32 
500 Hz -10.74 -10.40 -5.63 -1.47 
1000 Hz -12.39 -11.40 -5.77 -2.76 
2000 Hz -17.47 -15.07 -9.78 -5.10 
4000 Hz -27.63 -23.27 -14.67 -7.87 
6000 Hz -31.39 -26.29 -17.79 -7.21 
8000 Hz -35.23 -26.62 -18.16 -6.14 
10 000 Hz -33.02 -23.53 -14.19 -5.29 
12 500 Hz -23.50 -14.78 -8.49 -2.94 
 
Table 9 shows the parameter estimates of time for PTA across all test frequencies; 
the parameter estimates of time for each session are negative, therefore an increase can be 
expected. From table 9 it is obvious that the PTA threshold values, at each test frequency, 
for the parameter of time increases with each subsequent session. For example, at 250 
Hz; at session one, the PTA thresholds increases by 11.01 dB, at the second session the 
thresholds increases by 9.85 dB, in the third session, by 6.62 dB and in the fourth month 
the thresholds increases by 2.32 dB. The same can be said for all the other frequencies; 
and furthermore, these consequent increases in PTA thresholds are considerably higher at 
each session and at each consecutive frequency. Therefore, as the test frequency increases 
with each additional sessional assessment, so the PTA thresholds worsen. Therefore, it is 
evident that the pure tone threshold results at each test frequency increase from month to 
month in adult patients on long-term MDR-TB medication. 
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iv. DPOAE results compared to PTA results  
The audiological investigations that make up the audiological test battery cannot 
be viewed in isolation (Sweetow & Sabes, 2008). Since the otoscopic examinations and 
tympanograms had to correspond with the inclusion criteria of the study, no comparisons 
to the other audiological investigations need to be made as standard results were only 
accepted. However, the DPOAE and PTA results need to be viewed in a comparable 
manner, as results from one test need to correspond to the other test in order for the full 
audiological investigation to be permissible (Roeser, Valente & Hosford-Dunn, 2007). 
Therefore in this section results will be compared for the same sessions and for the same 
frequencies at which notable differences and similarities were found for DPOAEs and 
PTA thresholds. DPOAE results did not go past 8000 Hz whereas PTA results did; 
therefore no comparison can be made for the PTA results that were significant in showing 
hearing change i.e. at 10 000 and 12 500 Hz at any session.  
The DPOAE readings at session one showed that at 4000 Hz, the number of left 
ear refer readings (34) were notably lower than the number of right ear refer readings 
(42). Whereas, for the PTA mean threshold at this frequency at session one, the 
difference between left and right ear thresholds were not of great clinical difference i.e. 
17.5 dB and 16.54 dB respectively and these threshold readings fall within the range 
considered normal hearing. The ear difference effect at this 4000 Hz, at session one, was 
statistically non-significant. For the combined ear DPOAE readings at session one; both 
2000 and 3000 Hz had notably larger pass readings (91) than refer readings (45). 
Clinically, the PTA mean thresholds for these frequencies were still within the normal 
limits for hearing sensitivity. Statistically, the PTA changes were statistically significant 
(p<0.05) at 2000-4000 Hz. Despite the larger number of pass DPOAE readings, there still 
existed a number of refer DPOAE readings; and despite the PTA thresholds still being 
within normal limits there was a decrease from 250-2000 Hz in PTA thresholds. Perhaps 
the high pass rates are in agreement with the PTA thresholds remaining within normal 
limits; and the number of refer DPOAE readings are in agreement with the change or 
decrease in thresholds. No other comparable differences at session one existed.   
At the second session, clinically and statistically there was little comparison 
between the left and right results for DPOAE readings and PTA thresholds (p<0.05). 
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However, the overall results correspond clinically and statistically for DPOAEs and PTA 
at session two. The number of DPOAE refer readings at 4000-8000 Hz show an increase; 
and the change in hearing sensitivity for PTA results begins at 4000 Hz and continues on 
through to the remaining frequencies, and the p-values (p<0.05) are significant at session 
two and for frequencies 4000-8000 Hz.   
Session three shows clinically comparable differences between left and right ears 
for DPOAEs, but not for PTA results and not statistically (p>0.05) for DPOAE ear 
difference effect. However, the left ear DPOAE refer readings at 4000 and 6000 Hz show 
an increase in numbers as does the number of total DPOAE readings at 6000 Hz (left and 
right); and the change in hearing sensitivity for the overall PTA results begins at 4000 Hz 
and continues on through to the remaining frequencies. The analysis of covariance for 
PTA thresholds changes at 4000 and 6000 Hz, and ear effect at 6000 Hz are statistically 
significant (p<0.05) at this session.  
At session four, there are again clinically comparable differences between left and 
right ears for DPOAEs, but not for PTA results and not statistically (p>0.05) for DPOAE 
ear difference effect. For the comparison of the total PTA results and total DPOAE 
readings; at 2000 Hz the DPOAE readings show both refer and pass readings, but the 
number of pass readings are much higher than the number of refer readings at this 
frequency. The PTA threshold at 2000 Hz begins to change, and presents a mild hearing 
loss. This mild hearing loss corresponds to the number of refer readings at 2000 Hz.  
However, statistically the changes PTA threshold changes at 2000 Hz are non-significant 
at session four (p>0.05). Whereas at 4000-8000 Hz, the trend remains more constant, 
with remarkably lower pass numbers than refer numbers for DPOAEs and more severe 
hearing threshold changes from 4000 Hz onwards for PTA results. Statistically, only at 
4000-6000 Hz are the changes in hearing thresholds significant (p<0.05) at session four; 
and the changes in DPOAE function are non-significant (p>0.05).  
The fifth and final session for DPOAEs show large differences between the 
number of left and right ear DPOAE readings at 4000 Hz and the large refer numbers at 
250, 4000, 6000 and 8000 Hz in the total (left and right ear) results. As for the PTA 
results, the hearing loss is clinically evident across the entire frequency range.  
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Therefore, these audiological results confirm that adults on MDR-TB treatment over an 
extended period of time show permanent audiological changes and decreased hearing 
abilities. On analysis of variance, the changes in hearing thresholds were found to be 
statistically significant (p<0.05) from session one to session three for frequencies 250-12 
500 Hz; and for session four at 4000-6000 Hz. These differences are also considered 
statistically significant (p<0.05) for DPOAE and PTA results for sessions one (at 2000-
4000 Hz), session two (at 4000-8000 Hz), session three and session four (both at 4000-
6000 Hz). Similar for both left and right ears, the differences in PTA changes at session 
one to three (250-12 500 Hz) and session four (4000-6000 Hz) were statistically 
significant (p<0.05). Whereas, differences in ear effect for DPOAE readings were 
consider statistically non-significant (p>0.05) across all frequencies tested.  
 
3.3 Results of the estimated total sample of adults who may present with changes 
in hearing following long-term MDR-TB treatment  
3.3.1  DPOAEs 
As mentioned earlier in the study, an overall pass/refer was allocated to each 
patient’s DPOAE repeated measure done at each audiological session. This was based on 
a pass for more than 50% of the high frequencies (4000-8000 Hz). In this way the 
estimated number of adults who showed a change in hearing function (with regards to 
DPOAE function) could be calculated from the overall assigned pass/refer.   
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Figure 20  
Percentile Distribution of the overall assigned pass/refer for DPOAEs  
 
The pie chart (Figure 20) shows the percentile distribution of the overall assigned 
pass/refer for DPOAEs. Of the 68 patient files reviewed, the majority (57) of the sample 
(84%), over all five months of audiological assessments, were referred for DPOAEs.  
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Figure 21  
Distribution of the overall assigned pass/refer readings at each DPOAE frequency  
 
A more detailed graph, figure 21, shows the distribution of the overall assigned 
pass/refer rates at each DPOAE frequency. Looking into the distribution of frequency-
specific pass/refer rates is note-worthy as ototoxicity is said to be highly sensitive to 
DPOAE testing and is said to affect the high-frequencies first (Konrad-Martin et al., 
2005). At frequency 250 Hz, the percentage of the number of assigned overall passes is 
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lower than the number of assigned overall refers for the total sample. For frequencies 
750-1000 Hz, the number of pass/refer percentages are generally alike for the total 
sample readings. However, at frequencies 2000 Hz and 3000 Hz, the numbers of overall 
passes are higher than the number of overall refers in the total sample. This trend at 2000 
and 3000 Hz, is consistent with the number of pass/refer readings for DPOAEs at each 
audiological investigation across the DPOAE frequency range. At the higher frequencies, 
4000-8000 Hz, the number of overall assigned refers greatly exceeds the number of 
overall assigned pass numbers in the total sample.  
 
 
Figure 22  
Overall assigned DPOAE pass/refer reading for total sample at each follow-up session  
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percentage of pass readings are clearly visible from Figure 22. Furthermore, the gradual 
decline of pass readings at each subsequent audiological session is evident from the 
graph.  
3.3.2 Pure-Tone Audiometry  
The criteria set by ASHA (1994) according to their guidelines on management of 
ototoxic hearing loss, were used to indicate ototoxic hearing loss for each participant 
record, at each PTA assessment. These specific criteria are defined as (1) a 20dB 
decrease at any one test frequency, (2) a 10 dB decrease at any two adjacent test 
frequencies, or (3) a loss of response at three consecutive test frequencies where 
responses were previously obtained. 
 
 
Figure 23 
Percentage of total sample that present with ASHA (1994) criteria 
 
The most common seen criteria in the records reviewed were type (1), 83.24% of 
the sample presented with this criterion. Most type (1) criteria were seen in the patient 
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frequencies (10 000 and 12 500 Hz) (Figure 23). This 20 dB decrease was evident from 
session one. Then gradually, over the remaining four sessions, 20dB decreases were seen 
across the preceding frequencies. The 20 dB drop gradually moved into the mid-range 
frequencies (3000-8000 Hz) and was even seen in the low range frequencies (250-2000 
Hz) with some patient records.  Only 3.68% of the records reviewed matched the second 
criterion, and an even lower percentage matched type (3), 2.5% of the total sample. Of 
the 68 patient records reviewed, 19 showed two of the three ASHA criteria for defining 
ototoxic hearing loss. More specifically, five showed criteria (1) and (3), 13 showed 
criteria (1) and (2) and one showed criteria (2) and (3).  
Of the 68 patient records reviewed, all 67 presented with sensorineural hearing 
loss of some degree and configuration, according to the ASHA (1994) criteria for 
defining ototoxic hearing loss. Therefore it can be estimated that 98.53% of the group of 
adults had changes in hearing following long-term MDR-TB treatment. Only one patient, 
a female, showed no signs of ototoxic hearing loss. Her hearing was within normal limits 
for all PTA thresholds, except for one response at 12 500 Hz which was 30dB. However, 
no normative thresholds for HFA are available (Gordon et al., 2005). Her DPOAE 
readings began with pass readings at the first and second session, but the subsequent 
sessions were mostly refer readings across the DPOAE frequency range. This may 
indicate that her hearing was at risk given the DPOAE findings and there is research to 
suggest that DPOAEs may be reduced before threshold shifts occur at PTA (Bhagat, 
2009). It would have been beneficial had she attended follow-up sessions to monitor her 
hearing status and see if a hearing loss, due to ototoxicity, did develop over a longer 
period of time. In the total sample of patient records reviewed in this study, all 68 patient 
records showed a change in hearing function, be that changes in DPOAE function and/or 
changes in PTA thresholds, following long-term treatment for MDR-TB. 
3.4  Statistical results of the relationships between the audiological findings and 
variables in the total sample 
In this section, the possible relationships between the audiological findings 
(DPOAEs and PTA) and the following factors: age and gender were investigated using 
inferential statistics.  
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3.4.2 Logistical regression for DPOAE results in the total sample 
This section of the study intended to predict the probability of pass or refer in the 
DPOAE results.  
Table 10  
Parameter estimates and Odds of DPOAEs for age and gender effects 
 
 Parameters 
(B) 
S.E. Wald df P-
value 
Exp(B) 95.0% C.I.for 
EXP(B) 
Lower Upper 
Age -0.07 0.01 28.88 1 0.00 0.93 0.91 0.95 
Gender(1) -0.03 0.22 0.02 1 0.89 0.97 0.63 1.50 
Constant -0.01 0.55 0.00 1 0.98 0.99   
 
Table 10 represents the independent variables (age and gender effects) that may 
have significantly affected the DPOAE results over the five DPOAE screening sessions. 
The table clearly indicates that age is statistically significant (p<0.05), whereas the 
gender effect is non-significant (p>0.05). The Odds of a DPOAE result as being a pass 
reading, decreases by 0.93 as a patient’s age increases every year i.e. the effects of aging, 
as the parameter of age is negative. That is, generally the probability of passing on 
DPOAEs decreases with a patient’s age. For that reason, hearing function related to 
DPOAE results, decreases as a result of presbyacusis; but more significantly, the chances 
of passing DPOAE testing decreases as patients continue through monthly assessments 
related to ototoxic hearing loss, as seen in the DPOAE results section.  
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3.4.2 Analysis of Covariance (ANCOVA) for PTA results in the total sample  
Table 11  
ANCOVA Test Results of Between-Subject Effects for Independent Variables (age and 
gender) for PTA frequencies (250-12500 Hz) in total sample (N=68) 
 
Tests of Between-Subjects Effects 
Dependent Variable: Pure Tone Audiometry 
  250Hz     
p-value 
500Hz     
p-value 
1000Hz     
p-value 
2000Hz     
p-value 
4000Hz     
p-value 
6000Hz     
p-value 
80000Hz     
p-value 
10000Hz     
p-value 
12500Hz     
p-value 
Age 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Gender 0.22 0.73 0.62 0.76 0.02 0.04 0.05 0.16 0.08 
R value 0.07 0.06 0.07 0.08 0.15 0.18 0.21 0.25 0.28 
 
Table 11 is a summary of the ANCOVA analysis of between-subjects results for 
the variables of gender and age in the total sample across the PTA frequencies. In the 
ANCOVA analysis, across all the PTA test frequencies, the interaction effects for the 
variable of age had p-values of < 0.05. Therefore the independent variable of age is 
significantly different from zero. Therefore the hypothesis is rejected and the interaction 
effects of age are significant in this study. Whereas, the interaction effects for the variable 
of gender is non-significant (p> 0.05) across the PTA test frequencies, except for the 
interaction effect at 4000-8000 Hz (p<0.05). Therefore for all the other gender 
interactions across the PTA frequencies, the hypothesis is accepted and the interaction 
effects of gender are non-significant. However for 4000-8000 Hz, the gender interaction 
effect is significant. These results will be discussed further in the next chapter of this 
study.  
The R-squared values, indicates the total variance that the four interaction 
variables of gender, ear and time, have on PTA threshold results, whilst controlling for 
the effects of age (the covariate). At 250-2000 Hz, the total variance for PTA thresholds 
range between 61–83, and from 4000-12 500 Hz, the total variance increases to 146 and 
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continues to increase to 278. This means that after controlling for the age effect on the 
response variable, by accounting for age-related hearing loss in the exclusion criteria, the 
other variables explain the remaining variation in PTA thresholds. It has already been 
stated that ear effect was only found to be clinically significant at session two (6000 Hz) 
and session five (12 500 Hz). The R-values at these frequencies suggest that age was 
accountable for 25% of the PTA changes at 6000 Hz and 49% of PTA changes at 12 500 
Hz. 25% is minimal in comparison the remaining 75% change that the other variables 
may be accountable for. Whereas, 49% is a larger percentage that age may be 
accountable for. The interaction effects of all the variables will be discussed in the next 
chapter.  
Table 12  
ANCOVA parameter estimates for age and gender for PTA results across all test 
frequencies 
 
Parameter Estimates 
Dependent Variable: Pure Tone Audiometry  
P-values  
  Gender Age 
250 Hz 0.22 0.42 
500 Hz 0.73 0.38 
1000 Hz 0.62 0.47 
2000 Hz 0.76 0.49 
4000 Hz 0.02 0.45 
6000 Hz 0.04 0.57 
8000 Hz 0.05 0.62 
10 000 Hz 0.16 0.86 
12 500 Hz 0.08 1.27 
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Table 12 shows the parameter estimates of gender and age for PTA of the dummy 
variables resulting from the categorical variables, across all test frequencies. Table 12 
shows that across all the PTA test frequencies, 250-12 500 Hz, only gender is statistically 
significant (p<0.05) at 4000-8000 Hz. Age is non-significant (p>0.05) and the positive 
parameters of age at each frequency, indicate that the older the person, the higher the 
PTA threshold at each frequency. An increase of one year in age results in the increase of 
the PTA threshold at that frequency; and it is evident that age steadily increases in this 
group of adults on MDR-TB treatment. The current study did control for age-related 
hearing loss by excluding records of patients older than 49.11 years old.
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CHAPTER FOUR 
DISCUSSION 
 
4.1  Introduction 
As research literature supports, the relationship between anti-tuberculosis medications 
and hearing loss (Duggal & Sarkar, 2007; Human et al., 2010) has been well 
documented.  The current study looks at this relationship and adds relevance to the 
audiological and pharmaceutical fields within a South African context. The results 
following the retrospective review of hearing function in adults on long-term MDR-
TB treatment are discussed below in order of the audiological investigations they 
underwent. 
4.2  Discussion of the sample  
The sample consisted of 35 (51%) female records and 33 (49%) male records, 
between the ages of 18.00 and 49.11 years with a mean age of 33.4 years. The 
relatively small sample size, in relation to the large number of adults with MDR-TB 
within KwaZulu-Natal, was limited to available records that corresponded with the 
inclusion and exclusion criteria of the study. Therefore those records that indicated 
ages below 18.00 years and above 49.11 years, poor monthly adherence to 
audiological assessments, case history of previous hearing loss or conductive hearing 
loss, and defaulting of MDR-TB drug regimens were not considered in this 
retrospective study. However, the fact that the data were collected from a public 
health service hospital which provides health care service to the majority of South 
Africans, as opposed to a hospital within the private sector, the sample is more 
representative of the South African population. Acknowledgement has been made that 
the data were collected from only one institute, and generalisation to the larger South 
African population living with MDR-TB is limited. The proportion of male (49%) to 
female (51%) patient files was very similar in the total number of patient files 
reviewed. Therefore, gender effects, if any can be more equally discussed in this 
study.  
4.3  Otoscopic examination and Tympanograms 
In accordance with the inclusion and exclusion criteria set out for this study, 
only patient records with obstruction-free ear canals and Type A tympanograms at 
each audiological investigation, were considered for review. According to their 
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records, all 68 patient records revealed obstruction-free ear canals and Type A 
tympanograms at all five audiological sessions, including the baseline audiological 
investigation. These audiological tests were repeated measures, therefore the chances 
of false-positives arising are reduced and the results are more reliable and valid. The 
presence of type A tympanograms was used as an inclusion criterion to rule out 
common audiological impairments such as middle-ear infections and wax 
obstructions, that may confound the findings of this study. The implications of having 
conductive hearing losses in this study, would affect DPOAE and PTA results in a 
different way that a sensorineural hearing loss would; and therefore confounding 
variables would enter into this study. Conductive losses typically affect the lower 
frequencies in PTA, and DPOAEs results are usually absent (Glattke & Robinette, 
2007; Martin & Clarke, 2003). A Type A tympanogram indicates normal middle-ear 
pressure and compliance or a sensorineural hearing loss, where all other types indicate 
other abnormal findings (Margolis & Hunter, 2000).  Therefore it can be assumed that 
the patients, whose records were reviewed, presented either with normal hearing or a 
sensorineural hearing loss on tympanometry during their five months of audiological 
investigations. Further audiological testing is needed to verify findings and validate 
audiological testing using the cross-check principle (Shoup & Roeser, 2007). 
Therefore audiological testing has to be conducted in a battery of measures in order 
for accurate outcomes to be obtained (Sweetow & Sabes, 2008). Therefore it can be 
assumed that, in conjunction with the findings of DPOAEs and PTA, patients who 
presented with type A tympanograms were presenting with a probable sensorineural 
hearing loss. 
4.4  DPOAEs 
Screening DPOAEs were conducted at each audiological session, and yielded 
either a pass or refer reading for frequencies 250-8000 Hz. DPOAEs are a 
measurement of function and not threshold; a pass reading indicated that outer-hair 
cell function at that frequency was intact and hearing function as a result is 
unchanged. A refer reading indicated the opposite, and that hearing function would be 
altered by damage to the outer-hair cells of the cochlear (Bhagat, 2009). DPOAEs are 
considered a benchmark for detecting hearing dysfunction related to ototoxic hearing 
damage (Glattke & Robinette, 2007; Hall, 2000). The DPOAE results in this study 
were clinically and statistically investigated according to the changes the results had 
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on hearing function over time and also if other variables such as age, gender and ear 
difference impacted on these changes over time.  
The left and right ear DPOAE findings at all five sessions revealed some 
numerical differences in pass and refer readings for certain frequencies at certain 
sessions. However no definite trend could be ascribed to these findings and 
fluctuating differences between left and right ear readings were evident. The 
fluctuating differences can be explained by some of the literature that suggests lower 
frequencies are not as affected by ototoxic medication as the higher frequencies 
(Campbell, 2007) because the pathophysiological and pharmacological mechanism of 
aminoglycosides drugs operate in such a way that hair-cells responsible for higher-
frequency function are damaged first, followed by the mid- and lower-frequency hair-
sites (Steyger & Karasawa, 2008). Statistically, the ear performance effect was non-
significant across all five sessions. Indicating that in this study, no ear performed 
better or worse for DPOAEs. The above findings imply that the changes in hearing 
have taken on a more bilateral configuration; indicative of an ototoxic induced 
hearing loss (Konrad-Martin et al., 2005; Steyger & Karasawa, 2008). Specific 
literature could not be found suggesting ear difference in DPOAEs in the presence of 
ototoxic induced hearing loss. Conversely, the congruency in findings can be 
explained by literature regarding the close correlation between left and right ear 
responses for DPOAEs (Hall, 2000) and in a study by McFadden, Martin, Stagner and 
Maloney (2009) on DPOAE differences, no ear difference in DPOAE results were 
found.  
The total (left and right ear) readings from this current study, with regards to 
the overall number of refer readings across the five sessions, were interesting in that 
the results revealed high numbers of refer readings. This is not surprising because in 
the presence of hearing dysfunction, DPOAE results will present as refer readings 
(Hall, 2000).  Similar studies that looked at ototoxicity and hearing function did not 
include OAEs in their investigations (De Jager &Van Altena, 2002; Peloquin et al., 
2004); so no comparisons to this current study could be made. However, large 
volumes of research exist regarding OAE sensitivity to pre-clinical changes and their 
value in detecting frequency-specific hearing damage in OHC functioning (Hall, 2000 
& Konrad-Martin et al., 2005). This makes DPOAEs highly valuable in early 
detection of ototoxic hearing loss. This lack of information with regards to DPOAEs 
and ototoxicity highlights the need for more studies to be conducted in this context 
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that will include DPOAEs as part of the audiological investigations, so that effective 
and sufficient audiological data is available regarding this population of adults.  
As for the total DPOAE readings and the calculated number of adults who 
showed a change in hearing function (with regards to DPOAE function) over all five 
sessions and across all eight frequencies tested; these results were significant in this 
study as they revealed the presence of hearing dysfunction (i.e. refer readings) starting 
from session one at all the test frequencies through to session five.  This is unexpected 
because this study’s exclusion criteria stipulated participants with records of history 
of hearing loss and middle-ear pathologies be excluded; it was assumed that the 
records reviewed would be of patients with normal hearing sensitivity from the initial 
audiological assessment. Thus implying patients would present with a considerable 
number of pass readings for the DPOAE frequencies at the initial evaluation. 
However, most records reviewed displayed refer readings, as early as the initial 
evaluation and at the low frequencies. These results indicate that a hearing loss was 
already beginning when audiological measurements began, because OAEs are highly 
sensitive to pre-clinical (i.e. PTA threshold) changes (Konrad-Martin et al., 2005) 
especially changes related to ototoxicity (Khoza, 2007). Similarly, De Jager & Van 
Altena (2002) reported on the rapid appearance of ototoxic hearing loss within five 
days of drug administration. The presence of both pass and refer readings at all 
sessions and all frequencies could be due to three effects; firstly DPOAEs aid in the 
early identification of the start of ototoxic hearing loss, secondly that OAE’s are 
present in 99% of all ears (Hall, 2000) and thirdly that no DPOAE changes can occur 
in early exposure of ototoxic drugs (Bhagat, 2009).  The large percentage (84%) of 
the sample that showed a refer reading for DPOAEs revealed that the majority of the 
patients’ whose records were reviewed, showed a change in hearing function for 
DPOAEs over time. As with the above findings, the leading features in all the results 
are the high number of refer readings, as opposed to the number of pass readings at 
high frequencies (i.e. 6000-8000 Hz) across all five sessions. This above trend is 
consistent with literature (Campbell, 2007; Duggal & Sarkar, 2007; Konrad-Martin et 
al., 2005) that supports the notion that ototoxic hearing loss is characterized by 
changes in high-frequency hearing function, followed by changes in the mid and low 
frequencies (Konrad-Martin et al., 2005). 
Another variable that was investigated with relation to changes in DPOAE 
function was that of gender effect. There was also no statistical significance with 
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regard to gender differences in the DPOAE results across all five sessions and all 
frequencies. This finding is consistent with literature by Schmuziger et al. (2006) who 
assert that DPOAE amplitude is not influenced by gender. With regards to age as a 
variable affecting hearing fucntion related to DPOAEs, age was found to be 
statistically significant (p<0.05). That is, the probability of obtaining a pass result for 
DPOAEs decreases with age. These findings are supported by literature regarding the 
poor performance on OAEs with the deterioration of hair-cell function due to age 
(Hall, 2000), but most specifically at the ultra-high frequencies. The findings, in the 
current study, are concerning as age-related hearing loss was mostly accounted for in 
the exclusion criteria of this study. More research is required to confirm this age-
related association in the presence of ototoxic hearing loss.   
For that reason, the statistical significance that time has on DPOAE 
functioning when ototoxic treatment is present needs to be discussed. The statistical 
value of p (<0.05) for the time effect across sessions one to three were significant, and 
the odds of passing the DPOAE screening gradually decreases from session one 
through to session four; therefore over time the damage to outer hair cell functioning 
increased. In studies by Duggal and Sarkar (2007) and Li and Steyger (2009) 
regarding aminoglycosides and ototoxicity, prolonged exposure to ototoxic 
medication causes hair-cell damage in the cochlea that begins in the high-frequency 
range and progresses into the lower and mid-frequency range of the cochlea. 
Interestingly, the p-value at session four was non-significant (p>0.05). This could be 
attributed to the fact that all significant changes in hair cell function had already 
occurred, at the earlier sessions (De Jager & Van Altena, 2002; Li & Steyger, 2009) 
and that variability in the progression of ototoxic hearing loss is documented (Mudd 
et al., 2010). This highlights the need for standardised audiological ototoxic 
monitoring programmes, so that these changes can be identified early in the treatment 
process of MDR-TB and more information about such variability regarding ototoxic 
hearing loss patients can be obtained and better patient counselling and care can take 
place.  
The hearing function related to DPOAE results, may decrease as a result of 
age; but more significantly, the chances of passing DPOAE testing decreases as 
patients continue through monthly assessments related to ototoxic hearing loss. A 
number of audiological disorders affect DPOAEs; such conditions include increasing 
age and ototoxicity and can present similarly in DPOAE results. The changes seen in 
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DPOAE function in this study are more related to ototoxic hearing loss as age was 
accounted for in the exclusion criteria of the study.  It is clear from the above that the 
DPOAE screening in this population of adults on long-term MDR-TB treatment, has 
revealed the prolonged effects ototoxic medication has on hair cell function, 
specifically the primary effects on the higher frequency regions of the cochlea. 
Current findings suggest the need for further studies regarding audiological 
investigations into ototoxic hearing loss with DPOAEs be conducted so that literature 
pertaining to this context can account for variables such as age, gender and ear.   
4.5 High-Frequency Pure Tone Audiometry    
The next audiological investigation that was clinically and statistically 
analysed was that of PTA threshold results. PTA was conducted at all five sessions 
and the tested frequency range went up to 12 500 Hz. Internationally, PTA forms the 
basis of any hearing assessment (Roeser & Clark, 2007) and PTA is conducted to 
determine the presence, type, and degree of hearing loss in the peripheral auditory 
system based on behavioral responses to acoustic stimuli (ASHA, 2004). Intensity 
changes in hearing function were expressed in dB and clinical changes were described 
using Silman and Silverman’s (1991) classification of hearing loss system according 
to the mean thresholds for left ear, right ear and total threshold results.  
The results for left and right ear mean thresholds indicated that no changes in 
hearing thresholds at low frequencies (250-1000 Hz) from session one to session four 
occured, but rather at higher frequencies. Similarly, at session one the PTA thresholds 
for left and right ears were all within normal limits across the conventional PTA 
frequency range. Hearing changes in PTA were evident at the ultra-high frequencies 
(10 000 and 12 500 Hz). This collection of findings for left and right ear threshold 
results at session one, could be explained in two ways. Namely, that changes in 
hearing function due to ototoxic agents are characterised by damage to the high-
frequency in the cochlea (Harrell, 2002); and if any earlier damage to hearing function 
was present, PTA is not sensitive enough to detect early onset-ototoxic hearing loss, 
like DPOAEs are (Bhagat, 2009; Konrad-Martin et al., 2005). Therefore ototoxic 
audiological protocols should include multiple audiological investigations that can 
supplement and validate audiological findings (ASHA, 1994; WHO, 2010d).  
Overall, there was steady decline in left and right ear PTA thresholds across 
the frequency range and across the five sessions of audiological testing. The most 
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significant clinical changes occurred at the fifth session and at the highest frequencies 
in this group of adults on MDR-TB treatment. In a study by Duggal and Sarkar 
(2007), that also looked at the audiological outcomes of patients with MDR-TB on 
long-term treatment, found similar results with regards to sloping high frequency 
hearing loss. Likewise, in another study by De Lima et al. (2006), which investigated 
hearing impairment in individuals with TB using HFA testing, found the hearing loss 
was most severely affected at the high frequencies, and mostly bilateral and 
sensorineural in nature.  These findings in relation with this currents study’s findings 
means a trend can be established in developing countries on the presentation of 
hearing changes in patients on long-term MDR-TB treatment.  
Surprisingly, ear and gender had some significant standing at a few 
frequencies at some of the sessions, but little overall clinical significance at session 
one, session three and session four for each separate set of ear results. Literature 
previously published explains these inconsistent findings with regards to ear and 
gender effects. Inter-patient variations do exist and ototoxicity can be unpredictable, 
with individual variations in degree and range of hearing loss, susceptibility to 
ototoxic hearing loss and onset of hearing loss being evident (Begg & Barclay, 1995; 
Mudd et al., 2010). Another study investigating HFA (Wiley et al., 1998) found 
similar significant ear and gender effects at some lower frequencies, but no gender 
differences were observed in their threshold sensitivity at high frequencies. The 
inability for this current study, and others, to provide definite trends in gender and ear 
findings suggest that the hearing losses described had taken on a very bilateral 
configuration indicative of an ototoxic induced hearing loss (Konrad-Martin et al., 
2005; Steyger & Karasawa, 2008); and additional studies need to be done in South 
Africa to offer more research regarding these trends.  A bilateral hearing loss severely 
impacts on an individual’s communicative abilities, more than a unilateral hearing 
loss (Khoza, 2007). Providing counselling and rehabilitative measures, such as 
hearing amplification, may help patients deal with impaired localisation of sound 
skills and possible communication difficulties.  
In further describing the hearing loss in the sample that presented with clinical 
hearing loss in this study, the final results revealed a distinct mild-profound sloping 
SNHL. These results are consistent with literature that describes ototoxic hearing loss 
as a bilateral sensorineural hearing loss (Castillo & Roland, 2007). The severity of the 
hearing loss was more evident in the fifth PTA session. Statistically, the interaction 
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effects of time and age were significant across the entire five sessions and across the 
entire frequency range.  
Similarly, a study with adults aged 48-92 years old found that hearing 
sensitivity, for ultra-high frequencies, increased with advancing age (Wiley et al., 
1998). The study by Wiley et al. (1998) is useful in explaining the significance age 
had on the hearing threshold changes in the current sample. Other studies are in 
agreement that advancing age is a risk factor in the development of hearing loss in the 
presence of ototoxic medications (Kondrad-Martin et al., 2005). However, this current 
study controlled for advanced age by excluding participant records over 49.11 years 
of age. Other studies evidenced that ototoxicity is more common in adults than in 
neonates and children (Mudd et al., 2010).  Therefore, the findings that age was 
significant have more implications regarding the need for ototoxic monitoring 
programs in the adult population.  
Current findings in as far as PTA threshold changes are concerned revealed 
that time has a significant effect on thresholds when ototoxic treatment is being 
administered. Audiological changes were present in earlier sessions, but less severe 
and only at later frequencies. These findings are consistent with studies mentioned 
earlier (Duggal & Sarkar, 2007; De Jager & Van Altena, 2002), that also investigated 
HFPTA in adults on long-term treatment for MDR-TB. Findings from all these 
studies revealed mild-severe sloping sensorineural hearing losses that are consistent 
with research regarding the characteristics of ototoxic hearing loss (Castillo & 
Roland, 2007) and that lengthy exposure to ototoxic agents causes this type and 
degree of hearing loss. The presence of such a profound hearing loss has implications 
for the quality of life that such patients face and the role audiologists have on early 
and effective ototoxic monitoring programmes.  
ASHA (1994) established three criteria to interpret PTA thresholds as being an 
ototoxic hearing loss or not. ASHA established these criteria because monitoring for 
ototoxicity is not a common practice among audiologists and ototoxic treatment 
procedures.  Measurement and monitoring procedures tend to be inconsistent, and 
criteria for interpreting audiological results do not exist (ASHA, 1994). In this study it 
was found that the majority of the records showed type (1) criterion (83.24%); and 
only a small percentage of the records reviewed showed type (2) and type (3) criteria 
i.e. 3.68% and 2.5% respectively. As discussed, ototoxicity causes damage to the 
auditory structures responsible for high-frequency sound interpretation first. This is 
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seen in the large percentage of type (1) criteria where 20 dB drops in responses are 
evident across the monthly sessions; and the criterion was most evident at the highest 
frequencies (i.e. 8000-12 500 Hz).  This criterion was most evident at session one and 
gradually, over the remaining four sessions, 20 dB drops were seen across the 
preceding frequencies. All the patients had already begun MDR-TB drug 
administration before being referred for audiological investigations. This decrease in 
hearing sensitivity is consistent with literature which shows evidence of hearing loss 
seen within five days of aminoglycoside treatment commencement (De Jager & Van 
Altena, 2002). The time of onset of ototoxic hearing loss is unpredictable; and hearing 
loss may be evident after a single dose of treatment is given or several weeks after 
treatment has ended (De Jager & Van Altena, 2002). Risk factors and genetic 
predisposition may play a role in the development, and rate of development, of 
ototoxicity (De Jager & Van Altena, 2002; Konrad-Martin et al., 2005). This literature 
may explain the earlier appearance of ototoxic hearing loss in some patients than in 
others.  The hearing loss gradually moved into the mid range frequencies and was 
even seen in the low range frequencies with some patients. Hearing loss due to 
ototoxicity is predominantly in the high frequencies (Økstad, Laukli & Mair, 1988) 
and is most pronounced in the ultra-high frequencies (Dreschler, van der Hulst, Tange 
& Urbanus, 1985; De Seta, Bertoli & Filipo, 1985). The hearing loss gradually 
becomes evident in the lower frequencies throughout the treatment course (Fausti et 
al., 1994; De Jager & Van Altena, 2002; Schacht, 1998). Over time, highly ototoxic 
regimens can cause severe to profound hearing losses across the frequency spectrum 
(Duggal & Sarkar, 2007). The ASHA (1994) criteria used to indicate and define 
ototoxic hearing loss can all be done using pure-tone audiometry assessment, what is 
important is the frequency range that is incorporated to detect the three criteria i.e. 
HFA. HFA is successful in the early detection of ototoxicity (Dreschler et al., 1985) 
and is important in monitoring programmes as it provides warnings to take 
preventative and managerial measures before the frequencies, at which conversational 
speech occur, are affected (Schmuziger et al., 2007).  
A large limitation of using HFA is that there are no normative values for HFA 
thresholds (Schmuziger et al., 2007), due to issues such as lack of calibration 
standardisation, instrumentation, difference in testing procedures and inter-subject 
threshold variability (Gordon et al., 2005; De Set et al., 1985). Yet it is the most 
valuable and used measurement for detecting ototoxic-induced hearing loss (Frank, 
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1990; Gordon et al., 2005). Intra- and inter-subject variability are said to be due to the 
complex physical interactions of HF pure tones that may result in standing waves in 
the ear canal (Schmuziger et al., 2007).  
Despite the limitations of HFA use, a number of studies can justify the 
relevance and value of HFA with regards to repeatability and some threshold 
estimates. Dreschler et al. (1985) reported that HF reproducibility is almost as good as 
the reproducibility of the conventional frequency range (250-8000 Hz). Frank (1990) 
conducted HFA (10 000-20 000 Hz) with circumaural headphones, on 100 normal 
hearing adults, with an age range of 18-28 years old. The study found that test-retest 
thresholds were within the clinically acceptable range of ±1 0dB for each ear, for 95% 
of the subjects. Frank and Dreisbach (1991) found that HF thresholds were also 
repeatable and within a clinically acceptable range of ±10 dB in a study conducted 
with 50 otologically normal, mixed gender subjects using HFA with circumaural 
headphones. In a later study by Frank (2001), repeated thresholds for HFA were well 
within ±10 dB and had exceptionally low false-positive rates in reference to the 
ASHA (1994) criteria for a significant threshold shift due to ototoxicity. Another 
study by Schmuziger et al. (2004) made use of 138 otologically healthy mixed gender 
subjects with an age range of 12-51 years old. The study indicated 94% test-retest 
repeatability was within 10 dB for frequencies 500-16 000 Hz, with the 500-12 500 
Hz having excellent and the best repeatability with circumaural headphones. More 
recent studies investigate HFA thresholds. As reported by Comastri, Martin, Simon, 
Angarano, Dominguez, Luzzi, Lanusse, Ranieri and Boccio (2008), 70 patients of 
both genders, who were considered normal subjects, aged between 20 and 50 years 
presented with hearing within normal limits when tested at frequencies 8000-14 000 
Hz. In another study by Singh, Saxena and Varshney (2009), 50 normal patients of 
differing ages and gender with no history of hearing loss, ototoxic drug or noise 
exposure, were tested using ultra-high frequency PTA (8000-20 000 Hz). In the age 
groups ranging from 10-50 years old, the patients presented with hearing thresholds 
within normal limits for the ultra-high frequencies tested. The above findings lend to 
the reliability of the audiological findings, especially the value of HFA, in the current 
study. 
It is here that converging evidence from all the audiological investigation 
reviewed can be applied. The type A tympanograms can now be confirmed as a 
sensorineural hearing loss, as opposed to the other alternative (i.e. normal hearing) 
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with certainty. The DPOAE and PTA results show similar patterns of change in that 
the low- and mid-frequencies are affected by peripheral ear damage earlier than 
expected but with less severity; and the most change in ear function is seen at the high 
frequencies at the final audiological session; due to the pathophysiological and 
pharmacological mechanisms that aminoglycosides drugs show over long exposure 
times (Steyger & Karasawa, 2008). All the audiological test results indicate that this 
group of adults presented with sensorineural hearing loss of some degree and 
configuration over the five session time period. Some of these variations in the 
presentation, degree and range of hearing loss did exist for the ototoxic induced 
hearing loss (Konrad-Martin et al., 2005) as seen in this sample. Similar damaging 
effects on the human cochlea and other auditory changes can present as some of the 
criteria of ototoxic hearing loss, such as presbyacusis (Økstad, Laukli & Mair, 1988), 
HIV-related hearing loss (Roland, Alexiades, Jackman, Hillman & Shapiro, 2003) and 
excessive noise exposure (Schmuziger et al., 2007). However pre-existing HL, NIHL 
and presbyacusis were accounted for as exclusion criteria in this study. Therefore 
within this time frame, the only remaining possible hearing deficit in this study is that 
of ototoxicity.  
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CHAPTER FIVE 
CONCLUSION, LIMITATIONS AND RECOMMENDATIONS 
 
5.1  Theoretical Framework and Context of Study  
TB remains a world-wide pandemic; with MDR-TB on the rise globally 
(WHO, 2009a) and as of 2010, South Africa had about 11 000 cases of MDR-TB 
(2010b). Along with the increasing MDR-TB infections, the use of aminoglycosides 
is also on the rise in South Africa (Human et al., 2010). The ototoxic effects of MDR-
TB treatment cause permanent, sensorineural hearing loss (Human et al., 2010) that 
has negative effects on an individual’s life socially, vocationally and emotionally 
(Ross & Deverell, 2004; Khoza-Shangase et al., 2009; Swanepoel, 2006).  Despite the 
above findings, no standardised ototoxic monitoring programme is available to 
audiologically identify, monitor and manage such patients so that appropriate 
counselling and rehabilitative measures can take place. There is also no uniform drug 
regimen that will best facilitate the treatment of MDR-TB but also address adverse 
side-effects of the treatment. The record review took place at Murchison Hospital in 
KwaZulu-Natal province. This province has one of the worlds and South Africa’s 
highest MDR-TB rates (WHO, 2010b; Zager & McNerney, 2008).  This theoretical 
framework provided a necessary and urgent milieu for the content and context of this 
study.  
The aminoglycosides are an umbrella term for anti-TB drugs. They have been 
used to treat TB since the 1940’s (Begg & Barclay, 1995; Konrad-Martin et al., 2005). 
However, MDR-TB is resistant to first-line anti-tuberculosis drugs (Zager & 
McNerney, 2008). Well documented adverse effects of anti-TB drugs have been 
reported (Duggal & Sarkar, 2007) and undoubtedly the most significant limitation of 
the therapeutic use of aminoglycosides is their toxic and adverse effects on the 
auditory system (Konrad-Martin et al., 2005; Schacht, 1998). It would seem that 
preventing further cases of MDR-TB would require following an effective 
antituberculosis drug therapy regime. However, managerial supervision and provision 
of services appears to be a large hindrance to these regimens (Villarino et al., 1992). 
In South Africa such services are limited and resources scarce. Hospital institutions 
need to reduce patient-patient transmission of MDR-TB and improve early detection 
and management of infectious and at-risk patients. Many patients may go undetected 
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and remain infectious for prolonged periods of time due to ineffective medical 
management and long waiting periods for test results (Villarino et al., 1992). 
There are studies that investigated the effects of first-line anti-TB drugs on 
hearing function; they revealed ototoxic irreversible hearing loss, with permanent 
damage to auditory and vestibular systems (Khoza-Shangase et al., 2009; Konrad-
Martin et al., 2005; Li & Steyger, 2009; Peloquin et al., 2004; Schact, 1998).  Few 
studies have investigated the effects of second-line anti-TB drugs on hearing function. 
The few studies that have investigated the changes in hearing function with long-term 
use of aminoglycosides, found compelling research with regards to the initial damage 
being present at the high-frequencies and gradually progressing into the mid- and low-
frequencies of hearing range (Duggal & Sarkar, 2007; Jager & Van Altena, 2002). 
These studies did not include ototoxic-sensitive audiological tests, such as HFPTA or 
DPOAEs, or age, gender and ear effects in their findings. Therefore the results from 
this study are useful as all these factors were investigated.  
The effects of HIV in this environment cannot be excluded, given the high 
prevalence of HIV in South Africa, particularly in KwaZulu-Natal (UNAIDS, 2009), 
and the high co-infection percentage between HIV and MDR-TB (Suchindran et al., 
2009). However, HIV status and blood cell counts were not included in this study as 
the information was not readily available and the nature of a record review is that the 
researcher is limited to the data that already exists. Even if the researcher had 
requested for permission of HIV status and ARV regimens, those HIV positive 
patients could not be excluded as the sample needed to be a realistic representation of 
the population at hand; and many patients whose records were reviewed during the 
data collection had passed away. There is some index of suspicion on the nature of 
some of the audiological findings that HIV manifests in its own related hearing loss. 
However, the results indicated a typical-ototoxic hearing loss; with a high-frequency 
sensorineural hearing loss. Whereas literature suggests, HIV related hearing loss can 
be conductive, sensorineural and/or central, it can range from mild to profound, it can 
be gradual or sudden, stable or fluctuating and can be bilateral or unilateral. Otitis 
media is common and the hearing loss characteristics are often related to the 
progression of the disease (Khoza, 2007).  
There is no standardised ototoxic-sensitive audiological monitoring 
programme in this country, despite high numbers of TB, MDR-TB and HIV in our 
population (UNAIDS, 2009; WHO 2010b) and the unquestionable literature regarding 
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permanent hearing damage from treatment regimens for these infectious conditions 
(Khoza-Shangase et al., 2009; Duggal & Sarkar, 2007; Human et al., 2010).  
Therefore the outcomes of this study provide guidance and research data for the 
establishment of such ototoxic monitoring programmes in a South African context.  
5.2  Summary of Main Findings 
MDR-TB is a present and concerning illness in South Africa (WHO, 2010b). 
The study highlighted the severity and prevalence of hearing loss in an adult 
population receiving long-term MDR-TB treatment in South Africa. While 
investigating the hearing function in adults on long-term treatment for MDR-TB, 
findings from the current study indicated that adults receiving long-term MDR-TB 
presented with significant ototoxic hearing losses.  
- All 68 records reviewed revealed clinically clear otoscopic examinations and 
type A tympanograms at each audiological sessions 
- Changes in hearing function were seen in DPOAE and PTA results at all five 
audiological sessions and across all frequency ranges, with the time effect 
being the most significant variable in the data 
- 84% of the total sample presented with overall refer readings for DPOAEs 
- 98.53% of the group of adults presented with criteria indicative of ototoxic 
hearing loss  
- On clinical PTA results, 67 of the 68 records reviewed revealed a mild-
profound sloping SNHL  
- In the total sample of patient records reviewed in this study, all 68 patients 
showed a change in hearing function, be that changes in DPOAE function 
and/or changes in PTA thresholds, following long-term treatment for MDR-
TB 
- In summary, the hearing loss was mainly bilateral for the clinical PTA results 
- Variations in the effects of gender and ear difference were minimal and 
variations in the presentation of ototoxic hearing loss is common  
- Similar presentation, to ototoxic hearing loss, of other degenerative conditions 
exists; however these conditions were accounted for as exclusion criteria in 
this study. Therefore the only remaining possible hearing deficit in this study 
was that of ototoxicity  
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5.3 Limitations of the Current Study 
The study set out to investigate hearing function in a group of adults on long-
term MDR-TB, and provide relevant data regarding ototoxic hearing loss and in turn 
potential future recommendations for appropriate ototoxic monitoring programmes in 
South Africa. The nature of the study was that of a retrospective records review; 
therefore many of the limitations in the study are directly related to the fact that the 
researcher was limited to the information already available. The findings of this study 
need to be considered in relation to identified limitations of the research: 
- The hospital, at which the data were collected, was limited to screening 
DPOAEs up to 8000 Hz and not diagnostic DPOAE’s. DPOAE accuracy is 
increased when clinical information such as signal-to-noise ratio and primary-
tone frequencies are available (Bhagat, 2009). Had the hospital site had access 
to diagnostic OAE machinery that tested up to the same frequency that the 
PTA tested up to, more frequency specific results could have been obtained, 
more comparable high frequency results could have been made, and results 
described in more detail; increasing the study’s validity. However, despite this 
limitation, the researcher accounted for the limitation by ensuring only records 
with consistent results for all audiological assessments were reviewed so that 
repeatability strengthened the validity of the audiological test results.   
- As mentioned previously in the literature review; there exists a close link 
between HIV and TB (Gandhi et al., 2006; Goozé & Daley, 2003; Khoza, 
2007; Lawn et al., 2006). However, this study did not consider patients’ HIV 
status. Therefore, there was no co-investigation of hearing function with the 
possibility of patients having HIV/AIDS, or those possibly on ARV treatment 
for HIV and the interactions such treatments may have with MDR-TB 
treatments or the manifestations that HIV has on patients’ audiological system. 
There have been studies investigating the ototoxic effects of ARV’s and in 
combination with MDR-TB treatment may prove even more ototoxic (Khoza-
Shangase et al., 2009). Furthermore, it was reported in UNAIDS (2006), that 
approximately 18.8% of adults, in South Africa, aged 18-49 years old were 
infected with HIV. Therefore based on these statistics, the sample in this 
current study were between the ages of 18-49 years, it can be assumed that a 
percentage of the sample were possibly infected with HIV and possibly on 
treatment for HIV. For that reason, it would have been useful in this current 
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study to obtain patient information regarding possible HIV infection and 
treatment, so this could have been taken into account and or controlled for.  
- Patient case history was collected from patient records and subject to 
information probed by the Murchison audiologist at the time the patient was 
seen at the hospital. There is well-documented research (Konrad-Martin et al., 
2005) that states a genetic predisposition exists for ototoxic hearing loss. 
Therefore it would have been useful to include a thorough family history when 
starting a patient on ototoxic medication so those patients who are more at risk 
can be better counseled regarding their higher risk rates for the development of 
ototoxic hearing loss. This allows for patients to be better managed and 
monitored (Konrad-Martin et al., 2005) with regards to best practice standards 
for audiological care (ASHA, 2004).  
- As mentioned previously in the methodology section, it was a pre-existing 
limitation that record reviews are confined to the available and existing 
information. Therefore patient records did not include information or details 
on previous ototoxic drug regimens for other medical conditions or previous 
ototoxic exposure. Therefore to account for this limitation the researcher 
excluded any patient record that stated a previous hearing loss of any kind. 
- The audiological assessment in patients’ records did not account for tinnitus 
assessment or management.  The incidence of tinnitus with ototoxic hearing 
loss is unknown, as is the relationship between the two; tinnitus can occur with 
or without ototoxic hearing loss. Having had this information, on whether the 
patients in this study experienced tinnitus, would have added value in 
describing hearing function in the presence of ototoxic treatments.    
- Making use of statistics from global organisations comes with the drawback of 
having to deal with countries’ compliance in providing up-to-date data on 
infectious conditions such as HIV, TB and MDR-TB. Mathematical models 
allow for the generation of global estimates on such conditions. This is the 
case with most African countries, where large gaps in information exist due to 
poor patient compliance with treatment, poor diagnostic measures for 
determining incidences of such conditions and lack of infrastructure and basic 
medical care (WHO, 2010a).  
- Due to the fact that the researcher was dependent on available patient records 
and whether patients’ information matched the inclusion criteria, a larger 
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sample size could not be gathered. A larger sample size would allow for 
greater generalisation of the results and findings of the current study. Yet it 
gives insight into the reality of the current situation within the South African 
context, where audiological data is not readily available in a population where 
hearing loss is common in conditions such as TB and MDR-TB.  
5.4 Conclusions 
This study set out to review the audiological findings of adults on long-term 
MDR-TB medication. MDR-TB is a present and concerning illness in South Africa 
(WHO, 2010b). This study has highlighted the severity and prevalence of hearing loss 
in a South African adult population receiving long-term MDR-TB treatment and 
prompted the development of an ototoxic monitoring programme to meet the 
standards of audiological services in South Africa.  
In a group of adult patients receiving long-term MDR-TB treatment, all 
records reviewed showed hearing damage in some form and degree in both DPOAE 
and PTA results. The hearing loss was evidently found to be due to ototoxic damage 
to the ear structures. Findings from the study regarding the audiological changes that 
occur in patients with ototoxic hearing loss, has implications for when audiological 
management programmes should be implemented. As was evident from both the 
DPOAE and PTA testing, changes in hearing function were seen from session one, 
regardless of age, gender or ear performance. It is strongly suggested that audiological 
monitoring be implemented as soon as MDR-TB treatment commences or, better yet, 
as soon as the diagnosis of MDR-TB be confirmed so baseline results can be 
obtained. The high co-morbidity rate between MDR-TB and HIV also has 
implications for the implementation of an effective and efficient audiological 
monitoring programme. This population of people are at risk of contracting 
opportunistic infections. Monitoring systems can help identify and in-turn treat such 
infections so that further audiological deteriorating can be avoided. Guidelines for the 
control and prevention of MDR-TB transmission also need to be formulated and 
implemented in HIV units (Easterbrook, 1996).  
Audiological findings from all 68 records indicated that this group of adults 
presented with sensorineural hearing loss of some degree and configuration over time. 
The DPOAE and PTA results showed similar patterns of damage as indicated by their 
audiological implications. The changes began, early, in the high frequencies and then 
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gradually progressed into the low- and mid-frequencies. The final set of audiological 
results, indicating the time frame at which ototoxic treatment was the longest, 
presented with the most significant change in ear function. The cause of the hearing 
loss was confidently found to be due to ototoxicity due to the drugs 
pathophysiological mechanisms, the accountability for other auditory dysfunctions as 
being the cause and the ototoxic-like-characteristics of the hearing loss detected in all 
audiological tests reviewed in this study.  
5.5 Recommendations for Future Directions  
Despite the current study presenting with limitations, the study investigated 
the hearing function of adults on long-term MDR-TB in South Africa. It provided 
results and insight into the rapid and severe hearing loss that these patients presented 
with once on MDR-TB treatment. In addition to the valuable data on hearing function, 
it provides insight and opportunity about the role audiologists in South Africa need to 
play in the development and maintenance of an ototoxic monitoring programme to 
meet the standards of audiological services in South Africa. Furthermore, medical 
staff need to be on high alert for any signs of MDR-TB, especially in immune-
compromised patients with HIV (Easterbrook, 1996). 
De Jager and Van Altena (2002) found that patients are unlikely to complain 
of hearing loss until considerable hearing damage has been done. Therefore the ideal 
programme needs to include aspects of the audiological test battery that will be 
sensitive and specific to early detection and monitoring of ototoxic hearing loss. It 
needs to adhere to international and best-practice guidelines and standards; but also 
needs to be adapted for the South African context. Best-practice suggests the 
inclusion of detailed case history that includes probing on genetic predisposition to 
ototoxicity, HFA and diagnostic DPOAEs (ASHA, 2004). The inclusion of tinnitus 
information, as a part of the audiological assessment would optimise management for 
patients with ototoxic hearing loss (Konrad-Martin et al., 2005). 
As mentioned in the literature review, MDR-TB is a life-threatening condition 
and the use of treatment that is ototoxic is warranted to preserve life. The preservation 
of quality of life also falls within the scope of practice of medical professionals who 
are involved in the treatment, care and management of individuals with MDR-TB 
(Fausti et al., 2005).  The WHO Guidelines for the Treatment of TB (2010d), state that 
patients on treatment for MDR-TB should be monitored for the known adverse side 
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effects of drug-regimens and major adverse reactions. Monitoring ototoxic hearing 
loss may not prevent the ototoxic effects of the treatment; however evidence-based 
modifications to the dosing regimens may lower the adverse effects. This includes 
dividing dosages, using ancillary drugs, reducing the dosage or replacing the drugs 
(Campbell, 2007; Lüllmann et al., 2000; Gupta et al., 2008). More studies on the 
above need to be explored in relation to specific changes seen in the ototoxic hearing 
loss. Furthermore, an audiological monitoring programme will allow for the 
evaluation of rehabilitation measures, the confirmation of stable hearing thresholds 
and also function as an on-going counselling tool regarding the ototoxic hearing loss. 
Monitoring should ideally continue for at least six months after the cessation of 
treatment (Mudd et al., 2010) and appropriate hearing loss management and 
rehabilitation measures should take place to offer patients ,with ototoxic hearing loss, 
a better quality of life. Part of the role and duty of audiologists, is to provide effective 
and appropriate rehabilitation to patients diagnosed with hearing impairment. It is in 
audiologists’ professional capacity to maximize the patient’s residual hearing and 
offer education on their condition and possible treatment options (Martin and Clark, 
2003). Further research studies need to be conducted to decide on optimal length of 
the monitoring programme in this context.  
Other options to prevent or slow down ototoxic damage is to include 
protective antioxidants (Schacht, 1998; Steyger & Karasawa, 2008); these antioxidant 
agents may be too expensive and complex to be included in developing countries 
treatment protocols, but research showing high numbers of ototoxic hearing loss in 
the South African context is needed to advocate for such agents to be recommended to 
this country and other developing countries. Also drug regimens are often chosen on 
the basis of the local community’s resistance pattern (Gupta et al., 2008) and costs. 
More studies involving the effects of MDR-TB treatment are needed to change drugs 
and dosages and advocate for cost-effective but protective or anti-ototoxic drug 
treatments in South Africa. A rapid genetic screening method has been established 
that is easy, cost effective and efficient at detecting mutations in MDR-TB positive 
patients prior to the start of aminoglycoside treatment in order to lower the incidence 
of ototoxic-induced hearing loss (Human et al., 2010). Another interesting study that 
would give valuable information regarding the outcomes of audiological monitoring 
programmes in patients with MDR-TB, would be to compare treatment outcomes of 
partially hospitalized patients with outcomes of patient solely treated as outpatients. 
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Such a study would also give compellingly demonstration on the advantages of 
hospitalizing MDR-TB patients and the outcomes this has on MDR-TB incidence and 
infection rates.  
Therefore, it is recommended that further studies in South Africa be done 
involving the establishment of standardised guidelines for audiological monitoring, 
within a multidisciplinary team to advocate, effectively assess and manage patients on 
MDR-TB treatment. Proposed inclusion of the following into an ototoxic-monitoring 
programme for the South Africa population, based on the findings of this study 
suggests: 
- The following information needs to be obtained in a detailed case history and 
any changes during the monitoring time need to be obtained: previous or 
existing hearing loss, family history related to ototoxic hearing loss, the 
presence of tinnitus, commencement and end-date of ototoxic drug treatments.  
- The inclusion of DPOAEs, preferably diagnostic DPOAEs and HFPTA (at 
least up to 12 500 or 14 000 Hz) in the audiological investigations based on 
their sensitivity to the early and specific detection of ototoxic hearing damage. 
- Counselling measures need to be implemented from the start of monitoring 
and continue throughout the monitoring process. From this set of results and 
other literature, aspects regarding the type, degree and severity of the expected 
hearing loss need to be addressed as well as rehabilitation options post-
treatment.  
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Appendix A: Data capturing spreadsheet 
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Appendix B: Information Letter for Hospital Site 
 
ATT: Dr. W. Hardy  
Thank you for allowing me the opportunity to send this research proposal through 
regarding completing my masters in Audiology. My name is Angela Kavallieratos; I 
am a Masters student from the department of Speech Pathology and Audiology at the 
University of Witwatersrand. I will be conducting research for fulfilment of my 
Masters degree in Audiology. I will be conducting research regarding the effects of 
ototoxic drug administration for Multiple Drug Resistant Tuberculosis (MDR-TB). 
The aim of this proposed retrospective research is to determine the hearing function in 
adults with MDR-TB. Therefore I would like to review past patient audiological 
records from Murchison Hospital. Information regarding the hospital as well as the 
patients whose records will be reviewed will remain strictly confidential. Patient 
identifying information will not be published in results and patient details will remain 
anonymous. Ethical clearance is pending from the University of Witwatersrand 
Human Research Ethics Committee.   
 
It would therefore be much appreciated if the hospital would grant me permission to 
collect and utilize data from the MDR-TB unit for the purpose of completing my 
masters. The data and findings of my proposed research would be made available to 
the hospital on request for future quality improvement.  
Your anticipated participation in this study is greatly appreciated. Should you require 
the results of this study please indicate so and these will be provided in due time.  
 
Should you have any queries regarding the above please do not hesitate to contact me.  
Ms. Angela Kavallieratos  084 473 3154   
Supervisor: Mr. Victor Andrade 011 717 4570 
Co-supervisor: Dr. Katijah Khoza- Shangase  011 717 4565 
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Appendix D: Ethical clearance certificate obtained from Human Research Ethics 
Committee (Medical) 
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Appendix L: Pure Tone Audiometry Thresholds for total sample 
 
  Months Mean Standard Deviation Range 
Pure Tone Audiometry 
250 Hz 
1 15.074 15.295 105 
2 16.176 15.156 85 
3 19.412 21.231 110 
4 23.713 23.238 100 
5 26.029 25.071 110 
Pure Tone Audiometry 
500 Hz 
1 15.63 16.247 95 
2 15.919 15.241 85 
3 20.699 22.829 115 
4 24.853 25.188 115 
5 26.324 26.199 110 
Pure Tone Audiometry 
1000 Hz 
1 15.63 17.185 95 
2 16.581 18.04 100 
3 22.206 25.201 125 
4 25.221 27.527 125 
5 27.978 29.284 120 
Pure Tone Audiometry 
2000 Hz 
1 15.63 17.645 120 
2 17.978 19.526 110 
3 23.272 27.53 120 
4 27.353 28.29 125 
5 33.051 31.996 130 
Pure Tone Audiometry 
4000 Hz 
1 17.148 19.958 130 
2 21.471 22.045 120 
3 30.074 30.043 120 
4 36.875 31.64 115 
5 44.743 33.263 120 
Pure Tone Audiometry 
6000 Hz 
1 22.667 20.758 125 
2 27.721 24.128 120 
3 36.213 31.923 115 
4 46.801 32.833 115 
5 54.007 31.971 115 
Pure Tone Audiometry 
8000 Hz 
1 24.667 23.182 120 
2 33.235 26.257 110 
3 41.691 32.118 105 
4 53.713 30.368 110 
5 59.853 29.161 115 
Pure Tone Audiometry 
10000 Hz 
1 35.444 25.3 105 
2 44.853 26.659 100 
3 54.191 26.807 90 
4 63.088 24.751 85 
5 68.382 24.228 95 
Pure Tone Audiometry 
12500 Hz 
1 61.157 26.957 95 
2 69.596 26.063 95 
3 75.882 24.75 95 
4 81.434 21.343 85 
5 84.375 21.007 90 
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Appendix M: Pure Tone Audiometry Thresholds for left and right ears 
 
    Mean 
Standard 
Deviation Range 
Pure Tone 
Audiometry 250 Hz 
Left ear 21.209 21.975 110 
Right ear 18.997 19.541 105 
Pure Tone 
Audiometry 500 Hz 
Left ear 21.522 22.829 120 
Right ear 19.884 21.196 120 
Pure Tone 
Audiometry 1000 Hz 
Left ear 21.91 25.249 130 
Right ear 21.163 23.529 125 
Pure Tone 
Audiometry 2000 Hz 
Left ear 24.149 26.825 130 
Right ear 22.805 25.786 130 
Pure Tone 
Audiometry 4000 Hz 
Left ear 31.254 30.279 130 
Right ear 28.939 28.895 130 
Pure Tone 
Audiometry 6000 Hz 
Left ear 39.896 31.327 125 
Right ear 35.174 30.431 120 
Pure Tone 
Audiometry 8000 Hz 
Left ear 43.045 31.032 120 
Right ear 42.282 31.235 120 
Pure Tone 
Audiometry 10000 
Hz 
Left ear 53.701 28.367 105 
Right ear 52.747 27.983 100 
Pure Tone 
Audiometry 12500 
Hz 
Left ear 76.497 24.869 95 
Right ear 72.616 25.94 100 
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Appendix N: Statistical results from ANCOVA and Regression analyses  
 
Tests of Between-Subjects Effects 
Dependent Variable: Pure Tone Audiometry 250 Hz  
Source 
Type III Sum of 
Squares df 
Mean 
Square F P-value 
Corrected 
Model 20917.368(a) 7 2988.2 7.367 0 
Intercept 1330.73 1 1330.7 3.281 0.071 
Gender 606.79 1 606.79 1.496 0.222 
Ear 780.28 1 780.28 1.924 0.166 
Time 12202.6 4 3050.7 7.521 0 
Age 7949.2 1 7949.2 19.597 0 
Error 272177 671 405.63     
Total 567100 679       
Corrected 
Total 293095 678       
R Squared = .071 (Adjusted R Squared = .062) 
 
Parameter Estimates 
Dependent Variable: Pure Tone Audiometry 250 Hz  
Parameter B 
Std. 
Error t P-value 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Intercept 9.861 3.965 2.487 0.013 2.074 17.647 
[Gender=1] 1.96 1.603 1.223 0.222 -1.187 5.107 
[Gender=2] 0* . . . . . 
[Ear=1] 2.145 1.546 1.387 0.166 -0.892 5.181 
[Ear=2] 0* . . . . . 
[Time=1] -11.013 2.447 -4.501 0 -15.82 -6.208 
[Time=2] -9.853 2.442 -4.034 0 -14.65 -5.057 
[Time=3] -6.618 2.442 -2.71 0.007 -11.41 -1.822 
[Time=4] -2.316 2.442 -0.948 0.343 -7.112 2.479 
[Time=5] 0* . . . . . 
Age 0.422 0.095 4.427 0 0.235 0.61 
* This parameter is set to zero because it is redundant 
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Tests of Between-Subjects Effects 
Dependent Variable: Pure Tone Audiometry 500 Hz  
Source 
Type III Sum of 
Squares df 
Mean 
Square F Sig. 
Corrected 
Model 20190.292(a) 7 2884.33 6.275 0 
Intercept 2472.133 1 2472.13 5.378 0.021 
Gender 55.089 1 55.089 0.12 0.729 
Ear 414.034 1 414.034 0.901 0.343 
Time 13287.52 4 3321.88 7.227 0 
Age 6309.141 1 6309.14 13.726 0 
Error 308434.4 671 459.664     
Total 619350 679       
Corrected 
Total 328624.7 678       
R Squared = .061 (Adjusted R Squared = .052) 
 
Parameter Estimates 
Dependent Variable: Pure Tone Audiometry 500 Hz  
Parameter B 
Std. 
Error t Sig. 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Intercept 12.685 4.221 3.005 0.003 4.397 20.974 
[Gender=1] 0.591 1.706 0.346 0.729 -2.759 3.94 
[Gender=2] 0* . . . . . 
[Ear=1] 1.562 1.646 0.949 0.343 -1.67 4.794 
[Ear=2] 0* . . . . . 
[Time=1] -10.739 2.605 -4.123 0 -15.854 -5.625 
[Time=2] -10.404 2.6 -4.002 0 -15.509 -5.299 
[Time=3] -5.625 2.6 -2.163 0.031 -10.73 -0.52 
[Time=4] -1.471 2.6 -0.566 0.572 -6.576 3.634 
[Time=5] 0* . . . . . 
Age 0.376 0.102 3.705 0 0.177 0.576 
* This parameter is set to zero because it is redundant 
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Tests of Between-Subjects Effects 
Dependent Variable: Pure Tone Audiometry 1000 Hz  
Source 
Type III Sum of 
Squares df 
Mean 
Square F Sig. 
Corrected 
Model 27005.980(a) 7 3858 6.887 0 
Intercept 1296.2 1 1296.2 2.314 0.129 
Gender 134.806 1 134.806 0.241 0.624 
Ear 66.263 1 66.263 0.118 0.731 
Time 15672.01 4 3918 6.994 0 
Age 9796.674 1 9796.67 17.487 0 
Error 375901.1 671 560.21     
Total 717700 679       
Corrected 
Total 402907.1 678       
R Squared = .067 (Adjusted R Squared = .057) 
 
Parameter Estimates 
Dependent Variable: Pure Tone Audiometry 1000 Hz  
Parameter B 
Std. 
Error t Sig. 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Intercept 12.489 4.66 2.68 0.008 3.339 21.639 
[Gender=1] -0.924 1.883 -0.491 0.624 -4.622 2.774 
[Gender=2] 0* . . . . . 
[Ear=1] 0.625 1.817 0.344 0.731 -2.943 4.193 
[Ear=2] 0* . . . . . 
[Time=1] -12.394 2.876 -4.31 0 -18.04 -6.747 
[Time=2] -11.397 2.87 -3.971 0 -17.033 -5.761 
[Time=3] -5.772 2.87 -2.011 0.045 -11.408 -0.136 
[Time=4] -2.757 2.87 -0.961 0.337 -8.393 2.878 
[Time=5] 0* . . . . . 
Age 0.469 0.112 4.182 0 0.249 0.689 
* This parameter is set to zero because it is redundant 
 
 147 
 
Tests of Between-Subjects Effects 
Dependent Variable: Pure Tone Audiometry 2000 Hz  
Source 
Type III Sum of 
Squares df 
Mean 
Square F Sig. 
Corrected 
Model 39049.140(a) 7 5578.45 8.712 0 
Intercept 1973.478 1 1973.48 3.082 0.08 
Gender 59.884 1 59.884 0.094 0.76 
Ear 255.563 1 255.563 0.399 0.528 
Time 27048.26 4 6762.06 10.56 0 
Age 10508.05 1 10508 16.41 0 
Error 429657.9 671 640.325     
Total 842675 679       
Corrected Total 468707.1 678       
R Squared = .083 (Adjusted R Squared = .074) 
 
Parameter Estimates 
Dependent Variable: Pure Tone Audiometry 2000 Hz  
Parameter B 
Std. 
Error t Sig. 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Intercept 16.548 4.982 3.322 0.001 6.766 26.331 
[Gender=1] -0.616 2.014 -0.306 0.76 -4.569 3.338 
[Gender=2] 0* . . . . . 
[Ear=1] 1.227 1.943 0.632 0.528 -2.587 5.042 
[Ear=2] 0* . . . . . 
[Time=1] -17.472 3.074 -5.683 0 -23.509 -11.436 
[Time=2] -15.074 3.069 -4.912 0 -21.099 -9.048 
[Time=3] -9.779 3.069 -3.187 0.002 -15.805 -3.754 
[Time=4] -5.699 3.069 -1.857 0.064 -11.724 0.327 
[Time=5] 0* . . . . . 
Age 0.486 0.12 4.051 0 0.25 0.721 
* This parameter is set to zero because it is redundant 
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Tests of Between-Subjects Effects 
Dependent Variable: Pure Tone Audiometry 4000 Hz  
Source 
Type III Sum of 
Squares df 
Mean 
Square F Sig. 
Corrected 
Model 86568.781(a) 7 12367 16.369 0 
Intercept 8448.606 1 8448.61 11.183 0.001 
Gender 3945.982 1 3945.98 5.223 0.023 
Ear 785.83 1 785.83 1.04 0.308 
Time 68292.21 4 17073.1 22.598 0 
Age 9166.387 1 9166.39 12.133 0.001 
Error 506951.8 671 755.517     
Total 1207925 679       
Corrected Total 593520.5 678       
R Squared = .146 (Adjusted R Squared = .137) 
 
Parameter Estimates 
Dependent Variable: Pure Tone Audiometry 4000 Hz  
Parameter B 
Std. 
Error t Sig. 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Intercept 31.11 5.412 5.749 0 20.484 41.736 
[Gender=1] -4.998 2.187 -2.285 0.023 -9.293 -0.704 
[Gender=2] 0* . . . . . 
[Ear=1] 2.152 2.11 1.02 0.308 -1.991 6.296 
[Ear=2] 0* . . . . . 
[Time=1] -27.628 3.339 -8.273 0 -34.185 -21.071 
[Time=2] -23.272 3.333 -6.982 0 -29.817 -16.727 
[Time=3] -14.669 3.333 -4.401 0 -21.214 -8.124 
[Time=4] -7.868 3.333 -2.36 0.019 -14.412 -1.323 
[Time=5] 0* . . . . . 
Age 0.453 0.13 3.483 0.001 0.198 0.709 
* This parameter is set to zero because it is redundant 
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Tests of Between-Subjects Effects 
Dependent Variable: Pure Tone Audiometry 6000 Hz  
Source 
Type III Sum of 
Squares df 
Mean 
Square F Sig. 
Corrected 
Model 118388.919(a) 7 16912.7 21.38 0 
Intercept 13030.41 1 13030.4 16.472 0 
Gender 3284.715 1 3284.72 4.152 0.042 
Ear 3497.753 1 3497.75 4.422 0.036 
Time 91981.58 4 22995.4 29.069 0 
Age 14340.69 1 14340.7 18.128 0 
Error 530804.8 671 791.065     
Total 1604225 679       
Corrected 
Total 649193.7 678       
R Squared = .182 (Adjusted R Squared = .174) 
 
Parameter Estimates 
Dependent Variable: Pure Tone Audiometry 6000 Hz  
Parameter B 
Std. 
Error t Sig. 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Intercept 35.175 5.538 6.352 0 24.301 46.048 
[Gender=1] -4.56 2.238 -2.038 0.042 -8.955 -0.166 
[Gender=2] 0* . . . . . 
[Ear=1] 4.541 2.159 2.103 0.036 0.301 8.781 
[Ear=2] 0* . . . . . 
[Time=1] -31.396 3.417 -9.188 0 -38.106 -24.687 
[Time=2] -26.287 3.411 -7.707 0 -32.984 -19.59 
[Time=3] -17.794 3.411 -5.217 0 -24.491 -11.097 
[Time=4] -7.206 3.411 -2.113 0.035 -13.903 -0.509 
[Time=5] 0* . . . . . 
Age 0.567 0.133 4.258 0 0.306 0.829 
* This parameter is set to zero because it is redundant 
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Tests of Between-Subjects Effects 
Dependent Variable: Pure Tone Audiometry 8000 Hz  
Source 
Type III Sum of 
Squares df 
Mean 
Square F Sig. 
Corrected 
Model 138181.343(a) 7 19740.2 25.561 0 
Intercept 18428.09 1 18428.1 23.862 0 
Gender 3014.376 1 3014.38 3.903 0.049 
Ear 57.41 1 57.41 0.074 0.785 
Time 112955.7 4 28238.9 36.566 0 
Age 16857.49 1 16857.5 21.828 0 
Error 518195.4 671 772.273     
Total 1891975 679       
Corrected 
Total 656376.7 678       
R Squared = .211 (Adjusted R Squared = .202) 
 
Parameter Estimates 
Dependent Variable: Pure Tone Audiometry 8000 Hz  
Parameter B 
Std. 
Error t Sig. 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Intercept 41.277 5.471 7.544 0 30.534 52.02 
[Gender=1] -4.369 2.211 -1.976 0.049 -8.711 -0.027 
[Gender=2] 0* . . . . . 
[Ear=1] 0.582 2.134 0.273 0.785 -3.608 4.771 
[Ear=2] 0* . . . . . 
[Time=1] -35.233 3.376 -10.435 0 -41.862 -28.603 
[Time=2] -26.618 3.37 -7.898 0 -33.235 -20.001 
[Time=3] -18.162 3.37 -5.389 0 -24.779 -11.545 
[Time=4] -6.14 3.37 -1.822 0.069 -12.757 0.477 
[Time=5] 0* . . . . . 
Age 0.615 0.132 4.672 0 0.357 0.873 
* This parameter is set to zero because it is redundant 
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Tests of Between-Subjects Effects 
Dependent Variable: Pure Tone Audiometry 10000 Hz  
Source 
Type III Sum of 
Squares df 
Mean 
Square F Sig. 
Corrected 
Model 136818.430(a) 7 19545.5 32.732 0 
Intercept 22754.05 1 22754 38.106 0 
Gender 1168.471 1 1168.47 1.957 0.162 
Ear 91.454 1 91.454 0.153 0.696 
Time 97184.21 4 24296.1 40.688 0 
Age 32701.84 1 32701.8 54.765 0 
Error 400675.3 671 597.132     
Total 2460525 679       
Corrected 
Total 537493.7 678       
R Squared = .255 (Adjusted R Squared = .247) 
 
Parameter Estimates 
Dependent Variable: Pure Tone Audiometry 10000 Hz  
Parameter B 
Std. 
Error t Sig. 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Intercept 40.815 4.811 8.483 0 31.368 50.262 
[Gender=1] -2.72 1.944 -1.399 0.162 -6.538 1.098 
[Gender=2] 0* . . . . . 
[Ear=1] 0.734 1.876 0.391 0.696 -2.95 4.418 
[Ear=2] 0* . . . . . 
[Time=1] -33.015 2.969 -11.12 0 -38.845 -27.186 
[Time=2] -23.529 2.963 -7.94 0 -29.348 -17.711 
[Time=3] -14.191 2.963 -4.789 0 -20.01 -8.373 
[Time=4] -5.294 2.963 -1.787 0.074 -11.113 0.524 
[Time=5] 0* . . . . . 
Age 0.857 0.116 7.4 0 0.629 1.084 
* This parameter is set to zero because it is redundant 
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Tests of Between-Subjects Effects 
Dependent Variable: Pure Tone Audiometry 12500 Hz  
Source 
Type III Sum of 
Squares df 
Mean 
Square F Sig. 
Corrected 
Model 121966.490(a) 7 17423.8 36.788 0 
Intercept 38460.14 1 38460.1 81.203 0 
Gender 1463.13 1 1463.13 3.089 0.079 
Ear 2114.39 1 2114.39 4.464 0.035 
Time 48182.17 4 12045.5 25.432 0 
Age 71100.43 1 71100.4 150.118 0 
Error 317332.5 670 473.631     
Total 4205200 678       
Corrected 
Total 439299 677       
R Squared = .278 (Adjusted R Squared = .270) 
 
Parameter Estimates 
Dependent Variable: Pure Tone Audiometry 12500 Hz  
Parameter B 
Std. 
Error t Sig. 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Intercept 38.765 4.294 9.028 0 30.333 47.196 
[Gender=1] 3.049 1.735 1.758 0.079 -0.357 6.455 
[Gender=2] 0* . . . . . 
[Ear=1] 3.533 1.672 2.113 0.035 0.25 6.816 
[Ear=2] 0* . . . . . 
[Time=1] -23.495 2.649 -8.869 0 -28.696 -18.293 
[Time=2] -14.779 2.639 -5.6 0 -19.961 -9.597 
[Time=3] -8.493 2.639 -3.218 0.001 -13.675 -3.311 
[Time=4] -2.941 2.639 -1.114 0.265 -8.123 2.241 
[Time=5] 0* . . . . . 
Age 1.267 0.103 12.252 0 1.064 1.47 
* This parameter is set to zero because it is redundant 
 
 
